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ZUSAMMENFASSUNG 
 
Hepatitis B Virus (HBV) Infektionen verursachen entzündliche Erkrankungen der 
Leber. Insbesondere die frühen Phasen des HBV Lebenszyklus sind noch nicht geklärt, 
so ist z.B. der Rezeptorkomplex an den HBV bindet unbekannt. Mittlerweile stehen 
neue Infektionsmodelle zur Verfügung um den HBV Lebenszyklus zu untersuchen. 
Dies erfordert eine effiziente Zellkultur basierende Methode um große Mengen 
infektiöser Partikel zu generieren. Ein Ziel der Arbeit war durch Kultivierung auf 
Mikrocarrier die HBV Produktion der Zelllinie HepG2.2.15 zu steigern. Die Analyse 
von Protein und HBV Sekretion, Infektiösität und MAP Signalübertragung ergab eine 
18x höhere HBV Produktion bei einer reduzierten Sekretion von subviralen Partikeln 
durch HepG2.2.15 die auf Mikrocarrier kultiviert wurden. Der Anstieg der 
Virusproduktion korreliert mit einer verstärkten Aktivierung der MAP Kinase ERK-2, 
die mit HBV Replikation in Verbindung steht. 
Ein weiterer wenig verstandener Teil des HBV Lebenszyklus ist der Kernimport des 
HBV Genoms. Spuren der viralen Polymerase finden sich im Zellkern von HBV 
infizierten Zellen. Ziel der Arbeit war, Motive in der HBV Polymerase zu finden, die in 
der Lage sind Zelllokalisation zu beeinflussen. Durch Sequenzvergleich wurde eine 
konservierte zweiseitige Kernlokalisationssequenz im Terminalen Protein der HBV 
Polymerase identifiziert, die eine Proteinkinase CKII Erkennungsstelle enthält. 
Inhibition der CKII Aktivität in HBV infizierten primären Hepatozyten sowie die 
Zerstörung der CKII Erkennungsstelle im Terminalen Protein inhibieren die HBV 
Replikation. Die Funktionalität der Kernlokalisationssequenz wurde durch Fusion an 
GFP bestätigt und war Abhängig von CKII Aktivität in der Zelle. Dies wurde in vitro 
durch Bindung des Adapterproteins Karyopherin-alpha an CKII-phosphoryliertes 
Terminales Protein bestätigt. Die HBV Polymerase enthält eine konservierte zweiseitige 
Kernlokalisationssequenz deren Funktionalität durch CKII Phosphorilierung vermittelt 
wird. 
 
SCHLAGWORTE: Mikrocarrier, HepG2.2.15, HBV, Virologie, Polymerase, CKII, 
NLS, Kernimport 
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ABSTRACT 
 
Hepatitis B virus (HBV) infection causes acute and chronic liver inflammation. 
Especially the early phase of the HBV life cycle is not clearly understood. For example 
the receptor complex that mediates viral entry is not known. Novel infection models to 
study the HBV lifecycle are described that demand for a large amount of cell culture 
generated infectious HBV particles. One aim was to enhance HBV production of the 
cell line HepG2.2.15 by cultivation on microcarrier substrate. Analysis of protein and 
viral particle secretion, infectivity, and cellular MAP kinase signaling revealed an up to 
18x increased HBV production and a decreased subviral particle secretion by 
HepG2.2.15 when cultivated on microcarrier. The observed effect was due to an 
enhanced phospho-activation of MAP kinase ERK-2 that is tightly associated with HBV 
replication. 
Another poorly understood part of the HBV lifecycle is the mechanism that delivers the 
HBV genome into the nucleus. Traces of HBV polymerase can be found in HBV 
infected cells. The second objective was to identify motifs on the HBV polymerase that 
determine its subcellular localization. By sequence alignment a conserved bipartite 
nuclear localization signal was found in the terminal protein of the HBV polymerase 
encompassing a protein kinase CKII recognition site. Inhibition of CKII kinase in 
infected primary hepatocytes and destruction of the identified CKII recognition site in 
the viral polymerase impaired virus production. The functionality of the putative 
nuclear localization signal was confirmed by fusion to GFP. Moreover, its functionality 
was depended on CKII activity that was verified by in vitro binding experiments of 
terminal protein to the import adaptor karyopherin-alpha. This data identified a nuclear 
localization signal in the HBV polymerase, which functionality is mediated by CKII 
phosphorylation. 
 
 
KEYWORDS: microcarrier, HepG2.2.15, HBV, virology, polymerase, CKII, NLS, 
nuclear, import 
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1 INTRODUCTION 
 
1.1 Hepatitis B 
 
Hepatitis is an inflammatory liver disease. It can be caused by radiation, contusion, 
drugs, toxins or pathogens like bacteria, parasites or viruses. Most cases of hepatitis are 
due to virus infections. The known hepatitis viruses are classified in A, B, C, D, E and 
G and are non-related (beside C and G). Also some herpes viruses, Coxsackie virus, 
yellow fewer virus, adenovirus, paramyxovirus and rubella virus can cause a hepatitis 
phenotype [Gerok, et al., 2000]. 
 
1.1.1 Disease 
 
A hepatitis B virus (HBV) infection can be acquired by sexual contact and through body 
fluid transmission with blood contact, e.g. over lesions. The clinical symptoms of acute 
hepatitis are weariness, adynamia, headache, nausea, loss of appetite, elevated blood 
levels of transaminases, and symptoms of disturbed liver metabolism including icterus, 
cholestase, portal hypertension and dark urine [Gerok, et al., 2000]. In some cases the 
infection leads to fulminant hepatitis with severe complications including liver failure. 
Chronic hepatitis B is defined if the infection persists for more than 6 month. It can be 
asymptomatic although the viral surface antigen (HBsAg) is detectable in the blood of 
the patient. About 10 % of acutely HBV infected adults and 90 % of acutely infected 
children become chronically infected [de Franchis, et al., 2003]. Chronic hepatitis B 
infection can lead to liver cirrhosis and hepatocellular carcinoma [Gerok, et al., 2000]. 
 
1.1.2 HBV epidemiology 
 
It is estimated that 2 billion people worldwide have come into contact with HBV 
(positive for antibodies directed against viral core protein) and 400 million people are 
chronically infected with HBV [Buster and Janssen, 2006]. In the year 2000 about 
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250,000 incidences of hepatocellular carcinoma (HCC) were diagnosed worldwide in 
HBV carriers [Lupberger and Hildt, in press]. 
 
 
Figure 1: Worldwide prevalence of chronic hepatitis B. >8 % high prevalence (red), 2-8 % 
middle prevalence (yellow), <2 % low prevalence (green). Data based on WHO [Hollinger 
and Liang, 2001]. 
 
Regions with a chronic hepatitis B prevalence of 8-20 % of the population are defined 
as high endemic regions (Fig. 1, red). They include the population of Alaskan and 
Greenland Indians, the Amazon basin, sub-Saharan Africa, parts of the Middle East, 
Central Asian republics, Southeast Asia, and the Pacific basin (excluding Japan, 
Australia, and New Zealand) [Hollinger and Liang, 2001]. In China, Senegal, and 
Thailand the infection rate in infants exceeds 25 %. In Panama, New Guinea, Solomon 
Islands, Greenland, and in the population of Alaskan Indians the infection rates in 
infants are relatively low but increase rapidly during early childhood. [Hollinger and 
Liang, 2001]. In high endemic regions, about 70-90 % of the population becomes HBV 
infected before the age of 40. 
 
Areas with a chronic hepatitis B prevalence of less than 2 % of the population are 
defined as low endemic regions (Fig. 1, green). They include North and parts of South 
America, Western and Central Europe, Turkey, Japan, Australia, and New Zealand. In 
these regions less than 20 % of the population becomes HBV infected before the age of 
40 [Hollinger and Liang, 2001]. 
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The rest of the world falls under intermediate endemic regions (Fig. 1, yellow) with a 
chronic hepatitis B prevalence of 2-8 % of the population [Hollinger and Liang, 2001]. 
 
1.1.3 Prevention and treatment 
 
Immunization with recombinant HBV surface antigen has been available since 1986. 
An acute infection is usually not treated but monitored. The major target of the current 
treatment for chronic hepatitis B is the HBV polymerase. Its activity can be inhibited by 
nucleoside analogs (e.g. Lamivudine, Entecavir) and nucleotide analogs (e.g. Adefovir). 
But after long-term application of nucleos(t)ide-analogs the incidence of drug resistant 
escape mutants is high [Buster and Janssen, 2006]. Nucleos(t)ide-analogs are usually 
applied in combination with pegylated interferon-alpha, which stimulates the antiviral 
response of the host immune system [Buster and Janssen, 2006]. Nevertheless, there is a 
low chance for successful cure of a chronic HBV infection. 
 
1.2 Hepatitis B virus 
 
1.2.1 Genome organization and structure 
 
The hepatitis B virus belongs to the family hepadnaviridae that is subdivided into the 
genus avihepadnavirus (bird HBV e.g. Shanghai duck HBV, Ross goose HBV, China 
duck HBV, Heron HBV) and orthohepadnavirus (mammalian HBV e.g. human HBV, 
groundsquirrel HBV, woodchuck HBV). It has a partially double-stranded 3.2 kb DNA 
genome, in which coding sequences are organized into four overlapping and nested 
open reading frames (ORF) coding for seven viral proteins. All coded proteins are 
translated from 3-4 RNA transcripts (Fig. 2). 
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Figure 2: HBV genome organization. The 3.2 kb partial double-stranded DNA genome 
(center) harbors 7 overlapping and nested open reading frames: polymerase (P), X protein 
(X), core (C), E (Pre-C+C), large surface protein (PreS1+PreS2+S), middle surface protein 
(preS2+S), and small surface protein (S). The four viral mRNA transcripts are indicated 
with the size in kb: 0.7 kb, 2.1 kb, 2.4 kb and 3.5 kb pregenomic RNA transcript, with a 
redundant region harboring two direct repeats (DR). Figure modified from original [Kidd-
Ljunggren, et al., 2000]. 
 
The 3.5 kb pregenomic RNA (pgRNA) is an overlength transcript, which is an 
intermediate for virus replication and serves as a transcript for the translation of the 
90 kDa viral polymerase (ORF P), the 21 kDa core protein (ORF C), and a 24 kDa 
precursor early antigen (ORF preC-C) (Fig. 2). The preC region of the precursor protein 
harbors a signal sequence that directs the chain into the secretory pathway, where it is 
cleaved to a 16 kDa early antigen (HBeAg) and secreted to the bloodstream. The 
function of HBeAg is not known and HBeAg negative mutants replicate well in vitro 
and arise frequently during natural infections [Takahashi, et al., 1983]. The surface 
antigens (HBsAg) are translated from the 2.4 kb and the 2.1 kb mRNAs into the 42 kDa 
large surface antigen (ORF PreS1-PreS2-S), 31 kDa middle surface antigen (ORF 
PreS2-S) and 24 kDa small surface antigen (ORF S) [Seeger and Mason, 2000]. The 
0.7 kb mRNA is translated into the 16 kDa X protein, which is a regulatory protein 
[Twu and Schloemer, 1987; Wollersheim, et al., 1988]. The existence of the 0.7 kb 
mRNA has been verified in cell culture but not in vivo. 
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In the mature virus, the viral polymerase (P) is covalently attached to the 5’-end of the 
genome minus-strand. The P-genome complex is protected by an icosahedral capsid 
assembly consisting of the viral core protein (HBc). The HBV capsid is enveloped by 
host cell membrane, which is spiked with the small, middle, and large surface antigens 
(SHBsAg, MHBsAg, LHBsAg, respectively) [Seeger and Mason, 2000] (Fig. 3). 
 
 
Figure 3: HBV structure. A partial double-stranded DNA genome is bound 
covalently to the viral polymerase (P). The P-genome complex is enclosed by an 
icosahedral capsid consisting of core protein monomers. The viral capsid is 
enveloped by host membrane from the pre-Golgi compartment spiked with the viral 
surface proteins LHBsAg, MHBsAg, and SHBsAg. Image modified from James A. 
Perkins. 
 
In the blood of infected patients 42 nm infectious virus particles (Dane particles) are 
found together with an approximate 1000 fold excess of 22 nm sized subviral particles 
(SVPs) [Ganem, 1991] (Fig. 4). These spherical and filamentous structures consist only 
of HBsAg spiked viral envelope. The role of SVPs during infection remains unclear but 
it is speculated that the vast excess of SVPs compared to Dane particles is a kind of 
decoy that helps to mislead the immune system. Furthermore, it was suggested that SVP 
binding to the infected hepatocyte enhances viral replication due to a short-term 
transactivation of intracellular signaling [Bruns, et al., 1998]. 
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Figure 4: Electron microscopy of HBV particles. A = 42 nm Dane 
particle, B = 22 nm spherical subviral particle, C = 22 nm 
filamentous subviral particle (Image from Linda Stannard, University 
of Cape Town, South Africa). 
 
1.2.2 HBV species and subtypes 
 
Most viruses are able to adapt quickly to changing environments. Due to a lack of 
proofreading activity of the HBV polymerase the nucleotide substitution rate, per site 
and per year, is nearly as high as in retroviruses (10-5), but is 104 times higher than in 
DNA virus genomes [Orito, et al., 1989]. The HBV genotypes are defined as having 
sequence divergence of more than 8 % of the whole genome and at least 4 % divergence 
within the HBsAg reading frame. In early studies four major genotypes were described 
(A-D). During the last 15 years four additional genotypes (E-H) were postulated 
[Kramvis, et al., 2005]. The worldwide distribution of HBV genotypes and their 
phylogenetic relationship is shown in Fig. 5. 
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Figure 5: Phylogenetic relationship of HBV genotypes. 175 published HBV genomes 
are compared by neighbor-joining and are pictured as a single phylogenetic branch. 
Genotypes and their worldwide distribution are indicated: A (green) Asia, Japan, Africa, 
Europe, USA; B (light blue) Asia, Japan; C (purple) Asia, Australia; D (dark brown) 
worldwide; E (light brown) Western Africa; F (dark blue) South America; H (turquoise) 
Central America; G (pink) USA, France. Image modified from original [Kramvis, et al., 
2005]. 
 
The treatment of HBV can promote the appearance of “quasispecies” [Kramvis, et al., 
2005]. For example the use of nucleos(t)ide-analogs can cause drug resistant 
polymerase mutations that can also effect the overlapping HBsAg reading frame [Allen, 
et al., 1998]. Furthermore, it is described that selective pressure due to HBV vaccination 
can cause HBsAg mutations that escape the neutralization by vaccine-induced 
antibodies [Wilson, et al., 1999]. 
 
The viral surface antigen is exposed to the humoral immune response. The coding 
region of HBsAg is the most variable part of the viral genome due to the high selective 
pressure. Therefore, HBV is further classified in serotypes based on the heterogeneity of 
the HBsAg. Four serological subtypes (serotypes) were identified initially: ayw, adr, ayr 
and adw and have been expanded with the identification of further sub-determinants 
within the HBsAg [Kramvis, et al., 2005]. The predominant distribution of serotypes 
within the HBV genotypes and the consequence to the HBV polymerase ORF is shown 
in Table 1. 
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Table 1: Subtype (serotype) distribution in HBV genotypes. [Schaefer, 2005]. 
 
 
1.3 HBV lifecycle 
 
HBV productively infects only hepatocytes although it is discussed that it can enter bile 
ductule epithelium cells, some cells from the pancreas, kidneys, and from the lymphoid 
system presumably to ensure viral persistence [Seeger and Mason, 2000]. HBV has a 
non-lytic lifecycle and enters the hepatocyte by endocytosis mediated by the binding of 
the LHBsAg to an unknown receptor complex (Fig. 6). Inside the endosome the viral 
surface protein is probably cleaved by an unknown protease. This leads to a high 
density exposure of a cell permeable motif (TLM) within the PreS2 region of the 
LHBsAg that mediates the passage of the whole virus through the endosomal membrane 
[Stoeckl, et al., 2006]. 
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Figure 6: Scheme of the HBV lifecycle within a hepatocyte. Image modified from original 
[Kann, et al., 1995]. 
 
The endosomal processing and the reducing conditions probably lead to the uncoating 
of the envelope in the cytoplasm. It is discussed whether the P-genome complex is 
delivered into the nucleus by the intact nucleocapsid [Rabe, et al., 2003] or if a partial 
disassembly of the capsid within the nuclear pore complex or in a perinuclear domain 
leads to a release of the genome and its import into the nucleus [Brandenburg, et al., 
2005].  
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In the nucleus presumably the host DNA polymerases and repair mechanisms form a 
very stable non-integrated HBV mini-chromosome (cccDNA) [Zoulim, 2005]. cccDNA 
serves as a template for the host RNA polymerase II that transcribes the viral mRNAs 
(Fig. 2 & 6) that are transported to the cytoplasm where the viral proteins are translated. 
 
Upon steric activation by host chaperones Hsp90, Hsp70, Hsp40, Hop, and possible 
additional factors, the P protein binds to a secondary structure (ε) at the 5’-end of the 
pgRNA [Hu, et al., 2002]. A tyrosine residue of the polymerase serves as a protein 
primer that initiates reverse transcription, using a bulge within ε to initiate synthesis of 
the first 3-4 nucleotides of the minus-strand DNA [Wang and Seeger, 1993; Zoulim and 
Seeger, 1994]. The P protein serves as a reverse transcriptase and stays covalently 
attached to the nascent minus-strand of the HBV genome. The ε-structure recognition 
by P and the encapsidation by core protein oligomers are tightly coupled events 
[Bartenschlager, et al., 1990; Hirsch, et al., 1990]. 
 
For HBV nucleocapsid maturation phosphorylation [Melegari, et al., 2005] and 
dephosphorylation [Perlman, et al., 2005] of the viral core protein is required. The 
involvement of several cellular kinases are discussed, for example cdc2 [Liao and Ou, 
1995], SPRK1 and SRPK2 [Daub, et al., 2002], and an unknown 46 kDa protein which 
has yet to be characterized [Kau and Ting, 1998]. At least one molecule of protein 
kinase C (PKC) has been detected inside mature HBV virions [Kann, et al., 1993]. PKC 
phosphorylation of the core protein is proposed to be responsible for the docking of the 
capsid to the nuclear core complex during HBV infection [Kann, et al., 1999]. 
 
It is assumed that in the early stage of infection with low intracellular HBsAg levels the 
majority of mature capsids are directed to the nucleus to amplify the intranuclear 
cccDNA level to 10-50 molecules per cell [Newbold, et al., 1995]. In a latter phase 
mature HBV capsids are enveloped at a pre-Golgi compartment mediated by membrane 
associated viral surface proteins [Bruss, 2004] and secreted by the Golgi secretory 
pathway (Fig. 6). 
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1.4 HBV regulatory proteins 
 
Various regulatory functions are discussed for the HBV X protein [Bouchard and 
Schneider, 2004]. The integrity of X is essential for WHBV replication in woodchucks 
[Zoulim and Seeger, 1994] but not for HBV replication in the hepatoma cell line HepG2 
[Bouchard, et al., 2001]. HBx is a transcriptional activator that stimulates gene 
expression by several transcriptional factors e.g. NF-κB, AP-1, AP-2, ATF/CREB or the 
calcium activated factor NF-AT [Bouchard and Schneider, 2004]. Two major 
mechanisms of stimulation are described: (i) by direct binding of HBx to various 
members of the transcriptional machinery and e.g. enhancing DNA binding activity of 
transcriptional factor CREB or (ii) by stimulation of cytoplasmic signal transduction 
pathways. For example, it is found that HBx causes calcium release from the 
mitochondria leading to a subsequent activation of focal adhesion kinase (FAK), 
proline-rich tyrosine kinase (Pyk2), and Src kinases which results in a Ras-dependent 
activation of the mitogen-activated protein (MAP) kinase pathways c-Raf/MEK/ERK 
and MEKK-1/JNK [Bouchard and Schneider, 2004]. The stimulated MAP kinase 
pathways inhibit apoptosis and stimulate cell proliferation which results in enhanced 
HBV gene transcription in HBV infected cells [Peyssonnaux and Eychene, 2001]. 
 
The PreS2 region of the large and of the C-terminally truncated middle surface antigens 
has also a transcriptional activator function [Hildt, et al., 1996; Kekule, et al., 1990] that 
requires the integrity of the PreS2 domain and its cytoplasmic orientation as is given for 
a fraction of the large surface antigen [Bruss, et al., 1994]. PreS2 activates the c-
Raf/MEK/ERK pathway in a PKC-dependent Ras-independent manner that enhances 
gene transcription [Hildt, et al., 2002]. 
 
It was shown that the integrity of the c-Raf/MEK/ERK pathway is crucial for HBV 
replication and that HBx and PreS2 can replace each other in respect to 
c-Raf/MEK/ERK pathway activation [Stockl, et al., 2003]. 
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1.5 Infection models 
 
As already mentioned the receptors that trigger viral entry upon HBV binding are not 
identified yet. Immortalized hepatocyte cell lines are widely used for studying the 
mechanisms of HBV replication but the virus uptake during the early phase of HBV 
infection is blocked due to unknown reasons. Only a few infection models are available 
to study HBV infection because HBV is very tissue and species specific [Dandri, et al., 
2005]. Infection of primary human hepatocytes would be the most appropriate model 
but human liver tissue is only seldom available and the preparation of a sufficient 
amount of susceptible hepatocytes from a tissue sample is difficult. Another possibility 
is to study HBV infection in closely related viruses as the duck hepatitis B virus 
(DHBV) [Mason, et al., 1980], Heron hepatitis B virus (HHBV) [Sprengel, et al., 1988] 
or woodchuck hepatitis B virus (WHBV) [Aldrich, et al., 1989]. For example duckling 
liver tissue can be obtained easily and the preparation of hepatocytes by liver perfusion 
is more efficient. 
 
Chimpanzees can be infected by human HBV but this is controversial in an ethical point 
of view and the maintenance of the animals is extremely expensive. A few years ago it 
was found that HBV can infect and replicate in primary hepatocytes from the Asian tree 
shrew Tupaia belangeri [Kock, et al., 2001; Walter, et al., 1996] (Fig. 7). Furthermore, 
a HBV susceptible hepatoblastoma cell line was described that can be infected in the 
presence of corticoids and dimethyl sulfoxide [Gripon, et al., 2002]. All of these model 
systems require a large amount of human HBV with a defined genome to perform 
reproducible experiments. 
 
INTRODUCTION 
26 
 
Figure 7: Large asian tree shrew (Tupaia belangeri). 
Photo copyright Alan Hill (1@alan-hill.freeserve.co.uk). 
 
1.6 HBV particles for infection models 
 
Stably HBV genome transfected liver cell lines HepG2.2.15 [Sells, et al., 1987] or 
HepAD38 [Ladner, et al., 1997] continuously produce infectious human HBV particles, 
which can be used to study the HBV lifecycle in the current infection models. The 
conventional scale up of adherent mammalian cells in cell culture flasks is cost and 
space intensive. An efficient alternative is the cultivation of adherent cells on 
microcarrier, which are small particles floating in a cell culture suspension. It has been 
shown recently for retroviruses, adenoviruses [Wu, et al., 2002], and flaviviruses [Wu 
and Huang, 2002] that host cell cultivation on microcarrier can lead to a decrease or an 
increase of replication depending on the virus. The cultivation of adherent cells on 
microcarrier offers an advantageous cost-value ratio and less space consumption in 
comparison to conventional stationary culture flasks. If an intracellular product is 
targeted the removal of the cells from the substrate e.g. by trypsination or scraping is, 
depending on the carrier system, often not necessary. For example Cytodex-3 can be 
disrupted together with the cells and separated by centrifugation. Gong et al. (1998) 
cultured immortalized liver cells on Cytodex microcarrier and infected them with HBV 
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enriched patient serum in vitro. 58 days after infection they observed an up to 3.5 fold 
increase of extracellular HBV DNA compared to the initial HBV DNA level in the virus 
inoculum [Gong, et al., 1998]. 
 
1.7 HBV polymerase 
 
No crystal structure of the HBV polymerase (P) is available, yet a 3D model of the C-
terminal part was calculated according to structural similarities with the HIV and 
MMLV reverse transcriptases [Lin, et al., 2001]. The molecular weight of P is about 
90 kDa and it consists of three major domains (Fig. 8). The terminal protein (TP) 
domain is connected by a protein spacer (S) to the reverse transcriptase (RT) domain 
and the RNaseH domain at the C terminal end. The RT domain displays a reverse 
transcriptase activity and is functionally coupled to the RNaseH domain that degrades 
the RNA strand of a DNA/RNA hybrid. No enzymatic activity can be detected in the TP 
domain and the spacer, but tyrosine Y63 in TP acts as a protein primer during reverse 
transcription and stays covalently attached to the minus-strand within mature capsids. 
 
 
Figure 8: Scheme of the HBV polymerase (ayw). Amino acid positions are 
indicated above: 1-181 terminal protein domain (TP), 181-335 spacer (S), 335-681 
reverse transcriptase domain (RT), 681-832 RNaseH domain. Enzyme activities are 
only detectable of RT and RNase H. 
 
The TP and RT domains harbor protein binding sites for at least Hsp90 [Cho, et al., 
2000] and are important for ε-recognition and initiation of reverse transcription. ε-
recognition and reverse transcription by the RT domain can be complemented by 
addition of recombinant TP domain and chaperones in vitro. Due to this finding it is 
concluded that the spacer has only minor relevance for the functionality of the P protein 
in HBV replication [Lanford, et al., 1999; Lanford, et al., 1997]. 
 
The fate of the polymerase during and after the nuclear delivery of the genome is not 
known. The majority of P is localized in the cytoplasm bound to an unknown structure 
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[Yao, et al., 2000]. But a small portion of P protein is found also in the nucleus of duck 
HBV infected cells [Yao, et al., 2000]. If overexpressed, some P protein was found 
colocalized with the p11 protein of nuclear PML bodies interestingly in the absence of 
other viral proteins [Choi, et al., 2003]. Last but not least, Kann and co-workers 
reported that the P protein alone is sufficient to shuttle the bound genome into the 
nucleus [Kann, et al., 1997].  
 
1.8 Nuclear import mechanism 
 
In eukaryotic cells intracellular trafficking between the cytoplasm and the nucleus is a 
highly regulated mechanism. The nucleus is separated from the cytoplasm by the 
nuclear membrane that is interspersed with specialized channels. Such a channel 
consists of several proteins that form a nuclear pore complex (NPC) [Allen, et al., 
2000]. Molecules up to 9 nm (~20-40 kDa) can diffuse freely through the NPC in both 
directions. The passage of bigger molecules is either not possible or they are actively 
transported through the NPC [Goldfarb, et al., 2004; Mosammaparast and Pemberton, 
2004]. The active passage is mediated by a cascade of intracellular receptor proteins 
that recognize a distinct nuclear localization signal (NLS) on the cargo protein (see 
chapter 1.6). Karyopherin-β binds to the cargo-NLS either directly or mediated by the 
adaptor protein karyopherin-α (Fig. 9a). The karyopherin-cargo complex interacts with 
NPC proteins (Fig. 9b) that mediate the passage of the complex into the nucleus 
(Fig. 9c). Within the nucleus the binding of Ran-GTP to karyopherin-β leads to a 
release of the cargo, and the adapter karyopherin-α form the ternary complex (Fig. 9d). 
The karyopherin-β-Ran-GTP complex is shuttled back to the cytoplasm, whereas 
karyopherin-α is recycled by forming another ternary complex with the karyopherin-α 
export receptors CAS and Ran-GTP (Fig. 9e). In the cytoplasm the Ran-GTPase 
activating protein (Ran-GAP) causes dephosphorylation of Ran-GTP to Ran-GDP that 
leads to the release of karyopherin-α and karyopherin-β from their binding partners 
(Fig. 9f). 
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Figure 9: Karyopherin-α mediated shuttling of cargo into the nucleus. (a) The cargo protein 
(dark blue sphere) forms a ternary complex with karyopherin-α (red) and karyopherin-β (green) 
(b) the ternary complex binds to the NPC (c) and is actively transported into the nucleoplasm. 
The binding of terminator protein Ran-GTP (purple) to karyopherin-β leads to the release of 
karyopherin-α and its cargo (d). The karyopherin-β-Ran-GTP shuttles back to the cytoplasm. 
Karyopherin-α is recycled by binding to CAS-Ran-GTP that is exported to the cytoplasm  
(e) Dephosphorylation of Ran-GTP by Ran-GAP cause the release of the karyopherins into the 
cytoplasm. Image modified from original [Goldfarb, et al., 2004]. 
 
1.9 Nuclear localization signals 
 
Nuclear import signals bind to intracellular receptor karyopherins that mediate the 
nuclear import of the NLS-cargo. The best characterized NLS is derived from the large 
tumor antigen (T-ag) of the simian virus 40 (SV40) [Kalderon, et al., 1984], but various 
other motifs responsible for nuclear import were identified in other nuclear proteins 
(Tab. 2). Although a general hydrophilicity and some lysine/arginine rich cluster can be 
observed in motifs that binds to karyopherins, no general consensus sequence can be 
derived for monopartite NLS. 
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Table 2: Monopartite nuclear localization signals in nuclear proteins. The amino 
acid position of the NLS are indicated in superscript [Jans and Hubner, 1996]. 
 
 
Some proteins, e.g. polyoma T protein, influenza virus NS1 or Maze R protein harbor 
more than one NLS that are required in concert (Tab. 3). This increases the efficiency of 
the nuclear import and is needed especially to achieve complete nuclear localization of 
weak NLS [Shieh, et al., 1993]. A higher number of NLS in a protein seems to increase 
the import efficiency [Dworetzky, et al., 1988]. 
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A special variation of this multiple monopartite NLS are the bipartite class of NLS 
consisting of two series of basic clusters that are divided by a spacer of 10-12 amino 
acids (Tab. 3). The functionality of a prototype NLS sequence that was discovered 
within the nuclear chaperon nucleoplasmin in Xenopus laevis has been well 
characterized [Robbins, et al., 1991]. 
 
Table 3: Bipartite nuclear localization signals in nuclear proteins. The amino acid position of the 
NLS are indicated in superscript [Jans and Hubner, 1996]. 
 
 
A general consensus sequence was derived from nuclear proteins that harbor a 
functional bipartite NLS (K/R-K/R-(10-12 amino acid spacer)-K/R-K/R-K/R) (Tab. 3). 
The length of the amino acid spacer seems to have only minor effects on NLS 
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functionality although an increased hydrophobicity clearly reduces the nuclear import 
efficiency [Robbins, et al., 1991]. 
 
Bipartite nuclear localization signals usually bind karyopherin-α. The complex of a 
bipartite NLS and karyopherin-α was crystallized by Conti and co-workers in 2000 
[Conti and Kuriyan, 2000] (Fig. 10). The NLS binding domain is slug-like shaped and 
consists of ten helical repeat motifs (ARM). 
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Figure 10: Crystal structure of karyopherin-α2 (Saccharomyces cerevisiae) binding 
a bipartite NLS from nucleoplasmin (Xenopus laevis). Green = karyopherin-α2,  
blue = two basic clusters of the bipartite NLS separated by a 10 amino acid spacer (red). 
Image generated with PyMol from published PDB coordinates [Conti and Kuriyan, 
2000]. 
1.10 Regulation of nuclear import 
 
Some proteins like histones are constitutively targeted to the nucleus, whereas others 
like transcription factors remain in the cytoplasm until a distinct triggering event. Such 
regulation of subcellular localization was described and characterized e.g. for the 
glucocorticoid receptor, transcription factor NF-κB, sterol regulatory element binding 
protein SREBP-1, the yeast transcription factors xnf7 and SW15, and for the T-ag of 
simian virus 40. Various mechanisms by which the subcellular localization of proteins 
is regulated have been characterized. 
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1.10.1 Proteolysis 
 
Proteolysis of carrier proteins or binding partners can reveal a blocked NLS or remove 
an NLS dominant subcellular anchor. For example a 125 kDa precursor protein of 
SREBP-1 is C-terminally anchored to the ER and the nuclear envelope. Cleavage by a 
calpain like protease leads to the nuclear import of the N-terminal 68 kDa fragment 
mediated by the exposed NLS [Wang, et al., 1994]. Another example is the binding of 
IκB to transcription factor NF-κB, which overlaps (masks) the NLS of NF-κB and 
retains the protein in the cytoplasm. A phosphorylation of IκB triggers its proteolytic 
degradation and the exposure of the NLS of NF-κB that subsequently leads to its 
nuclear import [Lin, et al., 1995]. 
 
1.10.2 NLS masking 
 
Masking is defined as a blockade of a functional NLS by an interaction with another 
binding factor or a binding of another part of the molecule due to a conformational 
change. For example the NLS of the glucocorticoid receptor (GR) is blocked by an 
Hsp90 chaperone complex that retains the receptor in the cytoplasm [Picard, et al., 
1990]. GR is released if the corresponding hormone binds to the receptor. The 
subsequent exposure of the NLS triggers the binding of karyopherins that mediate 
nuclear import. 
 
1.10.3 Phosphorylation 
 
Protein phosphorylation is one of the main mechanisms to regulate subcellular 
localization. The best characterized example is the CcN motif of the T-antigen of simian 
virus 40 [Jans, et al., 1991; Jans and Jans, 1994]. Phosphorylation of the cell cycle 
dependent kinase cdc2 adjacent to the monopartite NLS of T-antigen inhibits nuclear 
import [Jans, et al., 1991], whereas phosphorylation upstream of the NLS by protein 
kinase CKII enhances nuclear import 40 fold [Jans and Jans, 1994]. This CcN motif is 
often found in proteins which are required in the nucleus at a distinct phase of the cell 
cycle. Beside CKII and cdc2, various other kinases are described to influence NLS 
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functionality, including PKC (lamin-B) or PKA (c-rel) [Jans and Hubner, 1996]. 
Bipartite NLS are also influenced by phosphorylation. In the case of nucleoplasmin, an 
upstream protein kinase CKII site of the bipartite NLS enhances the nuclear import of 
nucleoplasmin [Jans and Hubner, 1996; Vancurova, et al., 1995]. Immediate 
phosphorylation of one or two amino acids upstream of the crucial amino acid of 
classical monopartite NLS seems to have inhibitory effects on karyopherin binding due 
to a disturbance of the NLS basicity [Harreman, et al., 2004]. In the case of bipartite 
NLS this correlation is not evident. For example the spacer of the bipartite NLS of the 
Agrobacterium tumefaciens protein nopaline contains four negatively charged 
aspartates, one located immediately at the downstream basic cluster [Howard, et al., 
1992]. In the other hand an increase of the hydrophobicity of the 10-12 amino acid 
spacer seems to decrease its functionality [Robbins, et al., 1991]. 
THESIS OBJECTIVES 
36 
2 THESIS OBJECTIVES 
 
2.1 Upscale of HBV production 
 
Recently, novel infection models for studying the human HBV lifecycle have emerged 
[Gripon, et al., 2002; Kock, et al., 2001] demanding for large amounts of infectious 
HBV particles with a defined genome. Studies with various viruses infected cell lines 
have shown that variation of the cultivation substrate can alter virus replication and 
secretion [Wu and Huang, 2002; Wu, et al., 2002]. One aim of this study was to 
optimize HBV production by cultivation of the cell line HepG2.2.15 on spherical 
microsubstrate Cytodex-3 and to characterize the effects of this cultivation method on 
cellular signaling. 
 
2.2 Subcellular localization of the HBV polymerase 
 
The HBV polymerase is predominantly located in the cytoplasm but a small portion is 
also found in the nucleus of DHBV infected duck hepatocytes [Yao, et al., 2000]. Even 
in the absence of the viral core protein a small portion of the HBV P protein is found 
colocalized with PML bodies in the nucleus [Choi, et al., 2003]. Furthermore, P is 
sufficient for the import of the covalently attached HBV genome into the nucleus of 
digitonin permeabilized hepatocytes [Kann, et al., 1997]. Due to the fact that P is too 
big for free diffusion through the nuclear pore complex the second objective of this 
study was to identify motifs on the HBV polymerase, which determine the subcellular 
localization of the P protein during viral lifecycle. 
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3 MATERIALS 
 
3.1 Viruses, cells and animals 
 
3.1.1 Viruses 
 
AcNPV::HBV P Modified Autographa californica nuclear polyhedrosis virus for 
the expression of HBV polymerase [Lanford, et al., 1995] 
 
3.1.2 Bacterial strains 
 
Following Escherichia coli K12 strains were used in this study: 
 
DH5α Adjusted for molecular cloning purposes; recombinase A and 
endonuclease A deficient strain (DSMZ #6897). 
BL21 Adjusted for protein expression; deficient for proteases OmpT 
and Lon (Qiagen, Hilden). 
M15 (pREP4) Optimized for expression of toxic proteins; plasmid pREP4 
prevents promoter leakage prior to induction by overexpression 
of the coded lac repressor (Qiagen, Hilden). 
 
3.1.3 Cell lines 
 
Huh-7 Human hepatoblastoma cell line [Nakabayashi, et al., 1982]. 
HepG2.2.15 Human hepatoblastoma cell line harbors a 2.15 fold HBV 
genome (serotype ayw, genotype D) integrated into the 
chromosome [Sells, et al., 1987]. 
HepAD38 Inducible human hepatoblastoma cell line harbors a integrated 
tetracycline responsive 1.2 fold HBV genome (serotype ayw, 
genotype D) [Ladner, et al., 1997]. 
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Sf9 Derived from pupal ovarian tissue of Spodoptera frugiperda 
(DSMZ #ACC 125). 
 
3.1.4 Animals 
 
Asian tree shrew (Tupaia belangeri) were obtained from the German Primate 
Center in Göttingen, Germany and maintained in the animal 
facility of the University of Freiburg. 
Rabbit (Oryctolagus cuniculus) were obtained and maintained by the 
Bundesinstitut für Risikobewertung (BfR), Marienfelde, Berlin. 
 
3.2 Chemicals 
 
3.2.1 Plasmids 
 
Table 4: Plasmids and vectors. 
Plasmid Description Reference or source
peGFP-N1 27 kDa enhanced green fluorescent protein Invitrogen, Karlsruhe
pcDNA3.1(-) eukaryontic expression vector Invitrogen, Karlsruhe
pSM2 2.5 fold HBV genome, serotype ayw, genotype D (Sells et al. 1987)
pRV(P-) 1.2 fold HBV genome, serotype adr, P protein negativ Pairan A, unpublished
pQE60 bacterial expression vector, C-terminal (His)6-tag Qiagen, Hilden
pJo2 pQE60::TP domain (amino acid 1-181) of HBV P (ayw) this study
pJo3 pQE60::S domain (amino acid 182-340) of HBV P (ayw) this study
pJo19 1.2 fold HBV genome, serotype ayw, genotype D this study
pJo20 pJo19; P protein [T100I] this study
pJo21 pJo19; P protein [T53I] this study
pJo22 pJo19; P protein [T100I, T53I] this study
pJo23 pEGFP-N1, Δa1 of start codon eGFP this study
pJo37 pJo19; P protein [T53D] this study
pJo40 pJo19; P protein [K105Q, K106S] this study
pJo45 pJo19; P protein [T100D] this study
pJo47 pJo19; P protein [T100D, T53D] this study
pJo48 pJo23, BamHI  cloned NLS of nucleoplasmin (K142-K158) this study
pJo49 pJo23, BamHI  cloned NLS of HBV P protein (K100-R106) this study
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3.2.2 Synthetic Oligonucleotides 
 
Table 5: Synthetic Oligonucleotides. Nucleotide sequence starts at the 5’-end; bold indicated 
sequence is non-complementary to the template DNA; underlined sequence indicates relevant restriction 
sites. 6-FAM = 6-carboxlfluorescein, TAMRA = carboxytetramethylrhodamine, PH = phosphate ester at 
the hydroxyl group of the 3’-end, Y= C/T. All synthetic oligonucleotides were synthesized by  
Tib-Molbiol, Berlin. 
Primer Sequence (5'-3')
(cloning)
N-NLS-3b TTTAGATCTTTTTACTTTTTTCTGTGG
N-NLS-3f TTTAGATCTGTTCAGGGCCAGTGC
pEGFP-3b AGTCGCGGCCGCTTTACTTGTACAG
TP_f CCCGGATCCATGCCCCTATCCTATCAACAC
TP-NLS-3b TTTAGATCTTCTTTTCTCATTAACTG
(mutagenesis)
GFPΔstart_b CCTCGCCCTTGCTCACCATGGTGGCGACCGGTGG
GFPΔstart_f CCACCGGTCGCCACCATGGTGAGCAAGGGCGAGG
N-NLS-4b CCAGGGGCAGACCGCTTTCCCATGGTGGCGAGATCTACTTAAGAGTTTCACATCC
N-NLS-4f GGATGTGAAACTCTTAAGTAGATCTCGCCACCATGGGAAAGCGGTCTGCCCCTGG
T100D_b GGCAGGCATAATTAACTGCAATCTTCTTTTCTCATTAACGTCGAGTGGGCCTACAAACTG
T100D_f CAGTTTGTAGGCCCACTCGACGTTAATGAGAAAAGAAGATTGCAATTAATTATGCCTGCC
T100I_b GGCAGGCATAATTAACTGCAATCTTCTTTTCTCATTAACTATGAGTGGGCCTACAAACTG
T100I_f CAGTTTGTAGGCCCACTCATAGTTAATGAGAAAAGAAGATTGCAATTAATTATGCCTGCC
T53D_b GTAAAGTTCCCCACCTTATGGTCCCATGGAATACTAACATTGAGATTC
T53D_f GAATCTCAATGTTAGTATTCCATGGGACCATAAGGTGGGGAACTTTAC
T53I_b GTAAAGTTCCCCACCTTATGAATCCATGGAATACTAACATTGAGATTC
T53I_f GAATCTCAATGTTAGTATTCCATGGATTCATAAGGTGGGGAACTTTAC
TP-NLS-5f AAAAGATCTCGCCACCATGGTGAAAAAATGTGAACAGTTTGTAGG
ΔNLS_b CAGGCATAATCAATTGCAATCTAGACTGCTCATTAACTGTGAGTGGGCC
ΔNLS_f GGCCCACTCACAGTTAATGAGCAGTCTAGATTGCAATTGATTATGCCTG
(quantification)
HBx_b AGTCCAAGAGTYCTCTTATGYAAGACCTT
HBx_f CCGTCTGTGCCTTCTCATCTG
HBx_sonde 6-FAM-CCGTGTGCACTTCGCTTCACCTCTGC-TAMRA-T--PH
 
 
3.2.3 Molecular Weight Calibrators 
 
(Protein markers) 
Low molecular weight (LMW) GE Healthcare, Freiburg 
See blue Plus 2 Invitrogen, Karlsruhe 
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(DNA markers) 
peqGold 100 bp DNA ladder PeqLab, Erlangen 
peqGold 1 kb DNA ladder PeqLab, Erlangen 
 
3.2.4 Antibodies 
 
Table 6: Antibodies. Pab = polyclonal antibody; Mab = monoclonal antibody; HRP = horseradish 
peroxidase; Cy3 = cyanine 3; Cy5 = cyanine 5. 
Antibody Description Reference or source
(primary)
goat α-HBsAg Pab, detects hepatitis B surface antigen Dako, Hamburg
goat α-Hsp90-α Pab, detects human heat shock protein 90 α isoform Santa Cruz, USA
goat α-karyopherin-α2 Pab (C-20), directed against importin-α2 Santa Cruz, USA
mouse α-Pol (3552) Mab (clone 3552), detects HBV polymerase HPI Hamburg, unpublished
mouse α-β-actin Mab (clone AC-74), detects human beta-actin Sigma-Aldrich, Seelze
mouse α-CKIIα Mab, detects human protein kinase CKII α subunit Calbiochem, Darmstadt
mouse α-PCNA Mab (clone PC-10), detects human PCNA Santa Cruz, USA
rabbit α-ACTIVE Mabk Pab, detects phosphorylated form of human ERK Promega, Mannheim
rabbit α-α-Fetoprotein Pab, detects human α-Fetoprotein Chemicon, Darmstadt
rabbit α-PKCα Pab (C-20), detects human protein kinase C α subunit Santa Cruz, USA
rabbit α-PolS1 Pab, detects S-domain of HBV polymerase this study
sheep α-HBsAg Pab, detects hepatitis B surface antigen Uni Goettingen, unpublished
(secundary)
donkey α-goat-Cy3 Pab, conjugated with Cy3 dye Dianova, Hamburg
donkey α-goat-HRP Pab, conjugated with horse raddish peroxidase GE Healthcare, Freiburg
donkey α-rabbit-Cy5 Pab, conjugated with Cy5 dye Dianova, Hamburg
donkey α-rabbit-HRP Pab, conjugated with horse raddish peroxidase GE Healthcare, Freiburg
goat α-rabbit-Cy3 Pab, conjugated with Cy3 dye Dianova, Hamburg
sheep α-mouse-HRP Pab, conjugated with horse raddish peroxidase GE Healthcare, Freiburg
 
3.2.5 Enzymes 
 
Antarctic phosphatase NEB, Frankfurt am Main 
DNAse I Sigma-Aldrich, Sleeze 
DNase, RNase free Roche, Mannheim 
LunaTaq hotstart polymerase Bioline, Luckenwalde 
Lysozyme Carl-Roth, Karlsruhe 
Protein kinase C (catalytical subunit) Calbiochem, Darmstadt 
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Protein kinase CKII Calbiochem, Darmstadt 
Restriction endonucleases NEB, Frankfurt am Main 
T4 DNA ligase Roche, Mannheim 
BIOTAQ polymerase Bioline, Luckenwalde 
Pfu Ultra hotstart polymerase Stratagene, Netherlands 
 
3.2.6 Radiochemicals 
 
[γ32P]ATP Hartmann Analytics, Göttingen 
[α32P]dATP GE Healthcare, Freiburg 
[α32P]dCTP GE Healthcare, Freiburg 
 
3.2.7 Reagents for cell culture 
 
Collagenase CLSII Biochrom, Berlin 
Collagen G Biochrom, Berlin 
Dexamethasone Sigma-Aldrich, Sleeze 
L-glutamine PAN Biotech, Aidenbach 
Transferrin Invitrogen, Karlsruhe 
Sodium pyruvate PAN Biotech, Aidenbach 
Sodium selenite Invitrogen, Karlsruhe 
Bovine serum albumin Invitrogen, Karlsruhe 
DMEM medium (incl. L-glutamine) PAN Biotech, Aidenbach 
Trypsin / EDTA PAA, Austria 
Fetal calf serum (FCS) PAA, Austria 
G418 Sigma-Aldrich, Sleeze 
Hydrocortisone Sigma-Aldrich, Sleeze 
Insulin Sigma-Aldrich, Sleeze 
Penicillin / Streptomycin PAA, Austria 
SFII900 insect cell medium Invitrogen, Karlsruhe 
Williams medium E (w/o L-glutamine) Biochrom, Berlin 
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3.2.8 Inhibitors 
 
Table 7: Inhibitors. Effective concentrations are cited in brackets; an asterisk indicates IC50 
concentrations. 
Inhibitor Target Source
(Kinase inhibitors)
Gö6976 PKC isoenzymes α (2.3 nM*), β (6.2 nM*) Calbiochem, Darmstadt
DMAT protein kinase CKII (150 nM*) Calbiochem, Darmstadt
(Protease inhibitors)
Leupeptin serin-, cystein-proteases (4 µM) Sigma-Aldrich, Sleeze
Pepstatin acid-, aspartatic-proteases (1 µM) Sigma-Aldrich, Sleeze
Aprotinin serin-proteases (1 µM) Sigma-Aldrich, Sleeze
PMSF serin-, cystein-proteases (1 mM) Carl-Roth, Karlsruhe
 
 
3.2.9 Fine chemicals 
 
All fine chemicals were purchased by Carl-Roth, Karlsruhe. Exceptions are listed 
below: 
 
Aprotinin Sigma-Aldrich, Sleeze 
ATP Sigma-Aldrich, Sleeze 
GTP Sigma-Aldrich, Sleeze 
Bovine serum albumin (BSA) PAA, Austria 
Bradford reagent Sigma-Aldrich, Sleeze 
Cytodex 3 GE Healthcare, Freiburg 
DAPI Sigma-Aldrich, Sleeze 
DEPC Sigma-Aldrich, Sleeze 
Dichlorodimethylsilane Applichem, Darmstadt 
DMAT Calbiochem, Darmstadt 
dNTP mix Bioline, Luckenwalde 
ECL peroxidase substrate GE Healthcare, Freiburg 
Ethanol amine Sigma-Aldrich, Sleeze 
Ethidium bromide Applichem, Darmstadt 
Freunds adjuvant Sigma-Aldrich, Sleeze 
Fugene 6 transfection agent Roche, Mannheim 
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Gö6976 Calbiochem, Darmstadt 
GTP Sigma-Aldrich, Sleeze 
Imidazole Sigma-Aldrich, Sleeze 
Leupeptin Sigma-Aldrich, Sleeze 
NHS-sepharose GE Healthcare, Freiburg 
Nickel-NTA Superflow Qiagen, Hilden 
NP-40 Sigma-Aldrich, Sleeze 
Osmium tetroxide Bal-Tec, Austria 
Pepstatin Sigma-Aldrich, Sleeze 
Phalloidin-FITC Sigma-Aldrich, Sleeze 
Polyethylenimine (MW 25,000), linear Polysciences, USA 
Protein A/G agarose Santa Cruz,, USA 
Skim milk powder Sigma-Aldrich, Sleeze 
TEMED Sigma-Aldrich, Sleeze 
Triton X-100 Sigma-Aldrich, Sleeze 
tRNA Sigma-Aldrich, Sleeze 
TriFast Peqlab, Erlangen 
Tween-20 Gerbu, Gaiberg 
 
3.2.10 Drugs 
 
Ketavet (ketamine hydrochloride) Pharmacia & Upjohn, Erlangen 
Rompun (xylazine hydrochloride) Bayer, Leverkusen 
 
3.2.11 Membranes and relevant plastic ware  
 
Hybond-P GE Healthcare, Freiburg 
Hybond-N GE Healthcare, Freiburg 
T175 cm² cell culture flasks Greiner Bio-one, Frickenhausen 
Cell strainer BD Biosciences, USA 
Abbocath 18 gauge catheter Abbott, Ireland 
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3.3 Buffers and solutions 
 
Buffers and solutions are summarized in APPENDIX 1 
 
3.4 Kits 
 
High Pure Viral Nucleic Acid Kit Roche, Mannheim 
NEBlot probe labeling kit NEB, Frankfurt am Main 
QIAGEN Plasmid Maxi Kit Qiagen, Hilden 
QIAprep Spin Miniprep Kit Qiagen, Hilden 
QIAquick Gel Extraction Kit Qiagen, Hilden 
Enzygnost HBeAG Monoclonal ELISA Dade Behring, Marburg 
Enzygnost HBsAG 5.0 ELISA Dade Behring, Marburg 
 
3.5 Devices 
 
3.5.1 Chromatography 
 
Äkta Purifier chromatography system GE Healthcare, Freiburg 
MonoS 5/50 GL cationic exchange column GE Healthcare, Freiburg 
MonoQ 5/50 GL anionic exchange column GE Healthcare, Freiburg 
HiTrap Desalting gel filtration column GE Healthcare, Freiburg 
 
3.5.2 Electrophoresis 
 
Horizontal electrophoresis systems  
GNA 100 and 200 
GE Healthcare, Freiburg 
Vertical electrophoresis systems  
SE 260 and 600 
GE Healthcare, Freiburg 
Semi-dry blotting chambers  GE Healthcare, Freiburg 
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Semiphor and Multiphor II 
Hoefer Electrophoresis power supply 301 GE, Healthcare, Freiburg 
 
3.5.3 Microscopy 
 
Confocal laser scanning microscope (Axioplan) 
LSM510 
Zeiss, Jena 
Field emission scanning electron microscope LEO 
1530 
Carl Zeiss SMT, UK 
 
3.5.4 PCR cycler 
 
Lightcycler 1.5 Roche, Mannheim 
PegLab Primus 96 PegLab, Erlangen 
Taqman Abi Prism 4000 Perkin-Elmer, Rodgau 
 
3.5.5 Imaging 
 
Image plate reader BAS-1500 Fujifilm, Düsseldorf 
Intelligent Dark Box LAS-3000 Fujifilm, Düsseldorf 
Image plate BAS MP 2040S Fujifilm, Düsseldorf 
BAS Cassette 2040 Fujifilm, Düsseldorf 
AGFA CP-1000 film developer AGFA, Köln 
Biomax MR scientific imaging film Kodak, Stuttgart 
UV table UV-Biometra TB  
with camera BioToc 
Biometra, Göttingen 
 
3.5.6 Centrifugation 
 
Centrifuge 5415 R (refrigerated) Eppendorf, Hamburg 
Table centrifuge Biofuge fresco Heraeus, Osterode 
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Sorvall Evolution RC with rotors  
SLA-1500 and SS-34 
Sorvall Instruments, Bad 
Homburg 
Beckmann L8-70 ultracentrifuge  
with rotors SW-28 and SW-41 
Beckmann, USA 
Amicon Ultra-15 centrifugal  
filter device MWCO 100 kDa 
Millipore, Schwalbach 
Amicon Centricon Ultracel YM-10 centrifugal  
filter device MWCO 10 kDa 
Millipore, Schwalbach 
 
3.5.7 Other devices 
 
French Press Emulsi Flex C-5 Avestin, Canada 
Homogenisator Sonoplus HD 2070 Bandelin, Berlin 
Incubator Heraeus, Osterode 
pH meter 765 Calimatic Knick, Berlin 
Photometer Ultraspec 3300 pro GE Healthcare, Freiburg 
Satorius balance 1608 MP Satorius, Göttingen 
Satorius universal analytical balance Satorius, Göttingen 
Shaker Unitron HT-Infors, Switzerland 
Sterile bench HeraSafe Kendro, Langenselbold 
Thermomixer compact Eppendorf, Hamburg 
Vacuum dryer (Slap Dryer Model 443) BioRad, USA 
Vacuum pump KNF Neuberger, Freiburg 
Water bath GFL 1083 GFL, Burgwedel 
CPB-303 Critical point dryer Bal-Tec, Austria 
Polaron E5100 Sputter Coater Bal-Tec, Austria 
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4 METHODS 
 
4.1 Cell culture 
 
4.1.1 Prokaryotic cell culture and protein expression 
 
E. coli K12 strains DH5α, BL21 and M15 (pREP4) were cultivated in LB medium at 
37 °C with agitation in baffled Erlenmeyer flasks. For protein expression the E. coli 
strains were cultivated in SB medium. The strain M15 (pREP4) was cultivated with an 
additional 40 µg/mL kanamycin. Frozen stocks were stored in 25 % (v/v) glycerol at 
-80 °C. 
Protein expression was induced within the logarithmic growth phase at an optical 
density of 0.5-0.6 at a wave length of 600 nm by addition of 1 mM IPTG to the growth 
medium. After additional cultivation for 2-3 h the bacteria were harvested by 
centrifugation for 15 min at 6000x g, 4 °C. Pellets were stored at -20 °C. 
 
4.1.2 Eukaryotic cell culture 
 
The cell lines huh-7 and HepG2.2.15 were cultivated in DMEM medium including 
10 % (v/v) FCS, 0.1 U/mL penicillin, and 100 µg/mL streptomycin. The cell line 
HepAD38 was cultivated with an additional 2.5 mg/L insulin, 50 µM hydrocortisone, 
and 400 µg/mL G418. 
 
Primary hepatocytes of Tupaia belangeri were cultivated in Williams medium E, 
supplemented with 100 nM dexamethasone, 0.1 U/mL penicillin, 100 µg/mL 
streptomycin, 2 mM glutamine, 10 mg/L insulin, 6.7 µg/L sodium selenite, 5.5 mg/L 
transferrin, 110 mg/L sodium pyruvate, and 0.15 % (w/v) bovine serum albumin. All 
hepatocytes were cultivated attached to a collagen coated plastic surface at 37 °C in a 
water saturated atmosphere of 5 % (v/v) CO2. 
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Spodoptera frugiperda (Sf9) derived cells were grown in suspension with SFII900 
serum free insect cell medium at 27 °C and 135 rotations per minute. 
 
4.1.3 Adherent cell culture on microcarrier 
 
Cultures containing 6x106–2x107 cells per 20 mL were grown on 100 mg dw (dry 
weight) Cytodex-3 in a silanized 100 mL Erlenmeyer flask. The Cytodex-3 was 
equilibrated as suggested by the manufacturer except that the swollen microcarrier 
suspensions were not autoclaved. The microcarrier cultures were agitated by tilting 50 
times in 3 min, followed by a 30 min brake. This cycle was repeated for 24 h followed 
by 48 h nonstop agitation with the same frequency. Sampling was performed every 24 h 
by replacing the half of the culture media with fresh medium. Before its analysis, the 
samples were precleared by centrifugation at 300x g for 15 min. 
 
4.1.4 Cell trypsination 
 
Passaging of adherent cells was performed using trypsin / EDTA at 37 °C. Prior 
trypsination the cells were carefully washed with PBS buffer to remove cell culture 
medium. After 2-5 min the treatment was stopped by addition of 10 mL culture medium 
including fetal calf serum. If necessary, cell aggregates were minimized by a repeated 
passage of the cell suspension through a 20 gauge injection needle. The cells were 
seeded in fresh culture medium to reach 30-50 % confluency. 
 
4.1.5 Collagen coating 
 
The growth surface of a sterile cell culture dish was rinsed with 100 µg/mL collagen G 
solution. The collagen layer was air dried for 1-2 days until usage. 
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4.1.6 Silane coating 
 
A clean and dry 100 mL Erlenmeyer flask was rinsed with 5 % (v/v) 
dichlorodimethylsilane solution and baked for 1 h at 120 °C. The silanized glassware 
was rinsed with deionized water and autoclaved plugged with cellulose and aluminum 
foil. 
 
4.1.7 Cell counting 
 
Suspended eukaryotic cells were counted using a Neubauer chamber. The cells were 
diluted in 0.3 % (w/v) trypan blue to check for cell viability. 
 
4.1.8 Transfection of hepatoma cells 
 
For small scale transfections and endogenous polymerase assay analysis, huh-7 cells 
were transfected by lipofection using Fugene 6 according to the instructions of the 
manufacturer. For large scale transfections and if no further enzymatic reaction of 
extracellular products was necessary, cells were transfected using linear 
polyethylenimine (1 mg/mL) according to the manual of ExGene500 transfection agent 
(Fermentas, St. Leon-Rot). 
 
4.1.9 Preparation of primary hepatocytes 
 
Primary hepatocytes of Tupaia belangeri were isolated by liver perfusion with 
collagenase. Thereto, the animal was anaesthetized by injection of Ketavet 
(5 mg/100 mg body weight) and Rompun (1 mg/100 mg body weight) into the tail vein. 
After 10 min the animal was fixated and chest and belly were shaved and disinfected 
with 70 % (v/v) ethanol. The fur and the abdominal wall were opened and the organs 
rinsed twice with sterile Hanks solution, supplemented with 2.5 mM EGTA, 0.1 % 
(w/v) glucose, 0.1 U/mL penicillin, and 100 µg/mL streptomycin (Hanks I). An 
18 gauche catheter was inserted into the portal vein and the liver was purged at a flow 
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rate of 8 mL/min with Hanks I solution supplemented with 0.3 mg/mL 
collagenase CLSII and 5 mM calcium chloride. Immediately after starting the inferior 
cava vein and the right heart ventricle were incised to permit a sufficient outflow from 
the liver. The organ was perfused until the tissue swelled and lost its flexibility 
(Fig. 11). The liver was excised, the gall bladder was removed and the liver capsule was 
opened to release the cells into Williams medium E w/o glutamine, supplemented with 
100 nM L-hydrocortisone, 10 % (v/v) fetal calf serum, 1 µM insulin, 2 mM glutamine, 
0.1 U/mL penicillin, and 100 µg/mL streptomycin. Hepatocytes were enriched by 
centrifugation for 2 min at 37.5x g and sieved by a 70 µm cell strainer. 1x106 cells were 
seeded to a collagen coated 3.5 cm well. After 4 h the culture supernatant was removed 
and maintained as described in 4.1.2. 
 
 
Figure 11: Collagenase perfusion of Tupaia liver tissue. The liver was purged with 8 mL/min by 
0.3 mg/mL collagenase through a catheter in the portal vein until the tissue swelled and lost its flexibility. 
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4.2 RNA and DNA manipulation 
 
4.2.1 RNA preparation 
 
The RNA from eukaryotic cells was extracted using TriFast reagent according to the 
manufacturer’s instructions. The RNA was stored at -80 °C in RNAse free water. 
 
4.2.2 Virus DNA preparation 
 
4.2.2.1 Adsorber method 
 
Viral DNA was prepared from 500 µL cell culture supernatant using High Pure Viral 
Nucleic Acid Kit according to manufacturer’s instructions. The volumes of binding 
buffer and protease K solution at the first step were adapted to the increased sample 
volume. The virus DNA was stored in elution buffer at -20 °C. 
 
4.2.2.2 Phenol/chloroform method 
 
An equal volume of virus sample was mixed with lysis buffer (10 mM Tris-HCl, 6 M 
guanidine-HCl, 20 % (v/v) Triton X-100, 2.5 mg/mL proteinase K, pH 4.4) and 
incubated at 72 °C for 10 min. 
 
The virus DNA extraction was performed by phenol/chloroform treatment and ethanol 
precipitation as described in standard protocols [Ausubel, et al., 2004]. The virus DNA 
was solved in TE buffer and stored at -20 °C. 
 
4.2.3 Restriction enzyme reaction 
 
For qualitative analysis 1-2 µg of plasmid DNA and for cloning purposes 0.5 µg of 
vector DNA was digested in a 10 µL reaction volume according to the enzyme 
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requirements listed by the manufacturer. The DNA fragments were analyzed by agarose 
electrophoresis. 
 
4.2.4 Dephosphorylation of vector DNA 
 
Prior to ligation with insert DNA, the 5’-ends of linearized vector DNA were removed 
by Antarctic phosphatase treatment to prevent self-ligation. The reaction was performed 
according to manufacturer’s instructions in a 10 µL reaction. The phosphatase was 
inactivated by 5 min heat denaturation at 65 °C. 
 
4.2.5 Ligation of DNA 
 
Ligations were performed in a volume of 10 µL combining ~20 ng of linearized and 
dephosphorylated vector DNA and a 10 fold excess of insert DNA with compatible 
ends. The reaction was incubated overnight at 16 °C and finally heat inactivated for 
10 min at 65 °C. 
 
4.2.6 Transformation of DNA 
 
DNA was introduced into E. coli by calcium chloride mediated transformation as 
described in Current Protocols of Molecular Biology [Ausubel, et al., 2004]. The 
chemically competent cells were prepared according to basic protocol 1, shock-frozen 
in liquid nitrogen and stored at -80 °C. The colonies were checked by PCR (4.2.8.1) for 
positive clones and correct ligations. 
 
4.2.7 Plasmid extraction 
 
Plasmid DNA was extracted from bacterial biomass using QIAprep Spin Miniprep Kit 
from a 3-5 mL overnight culture or QIAGEN Plasmid Maxi Kit from a 200-500 mL 
overnight culture. The extraction procedure was performed as described by Qiagen. The 
plasmid DNA was eluted in EB buffer and stored at –20 °C. 
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4.2.8 Polymerase chain reaction (PCR) 
 
4.2.8.1 Standard PCR 
 
Qualitative or preparative DNA analysis by PCR was performed in a reaction mix 
described in Tab. 8. The target DNA was amplified at 95 °C 6 min, 29x (95 °C 60 sec, 
52 °C 60 sec, 72 °C 90 sec), 72 °C 10 min. For colony PCR a small portion of the 
bacterial colony was suspended in 20 µL deionized water. 2 µL of the bacteria 
suspension was used as sample for PCR. 
 
Table 8: PCR reaction mixtures. 
Reagents Standard PCR Mutagenesis TaqMan PCR Lightcycler PCR
Reaction volume (50 µL) (50 µL) (50 µL) (20 µL)
10x PCR buffer w/o MgCl2 5 µL 5 µL 2 µL
10x Pfu  reaction buffer 5 µL
MgCl2 (50 mM) 2.5 µL 4.5 µL 1.8 µL
TE buffer, pH 8.0 0.8 µL 0.24 µL
BSA (600 µg/mL) 0.24 µL
dNTP mix (25 mM each) 0.4 µL 0.25 µL 0.4 µL 0.32 µL
sense primer (10 µM) 1.25 µL 1.25 µL 1.25 µL 0.5 µL
antisense primer (10 µM) 1.25 µL 1.25 µL 1.25 µL 0.5 µL
probe (10 µM) 0.625 µL 0.25 µL
BIOTAQ polymerase 0.25 µL
LunaTaq hotstart polymerase 0.25 µL 0.1 µL
Pfu  hotstart polymerase 1 µL
Sample 2 µL 1µL 2 µL 1 µL
(≤20 ng plasmid) (5-20 ng plasmid)
 
4.2.8.2 Quantitative PCR 
 
For the quantification of target DNA molecules two systems were used: the high 
throughput TaqMan system Abi Prism 4000 and the faster low throughput Lightcycler 
1.5 system. The principle of quantification is the detection of a third fluorescent linked 
oligonucleotide (probe), which binds in between the two binding sites of the primer set. 
In this study quantitative PCR systems were instrumental to quantify a 124 basepair 
METHODS 
54 
(bp) DNA sequence within the HBV genome. This HBV assay was first described 2003 
by Stoeckl and co-workers [Stockl, et al., 2003]. 
 
The PCR reaction mixtures for the TaqMan and the Lightcycler formats are summarized 
in Tab. 8. The TaqMan temperature profile was 95 °C 5 min, 30x (95 °C 15 sec, 60 °C 
60 sec) and the Lightcycler temperature profile was 95 °C 5 min, 30x (95 °C 15 sec, 
60 °C 30 sec, 72 °C 30 sec). 
 
4.2.8.3 Site directed mutagenesis 
 
This PCR based method introduces site directed mutations in circular plasmid DNA by 
a set of reverse complementary oligonucleotides [Fisher and Pei, 1997]. The sequence 
alteration was coded in the central part of the backward and the forward primer, which 
was flanked upstream and downstream by at least 20 bp of complementary sequence. If 
possible a silent marker mutation was introduced near the crucial mutation, which did 
not affect the amino acid sequence but altered the restriction pattern of the plasmid. 
 
A Pfu polymerase with proof reading activity amplified both strands of the plasmid 
starting at the same position in opposite directions. The reaction mix composition is 
described in Tab. 8. The template DNA was amplified at 95 °C 30 sec, 18x (95 °C 
30 sec, 55 °C 60 sec, 2 min/kb of plasmid length). The annealing temperature in this 
method is set independently of the actual melting point of the primers because of the 
unusual length of the mutation primers (Tab. 5). Prior transformation in E. coli DH5α 
the template DNA was digested with restriction endonuclease DpnI. Candidate plasmids 
were preselected by PCR and restriction analysis. Finally, the mutated plasmid was 
verified by sequence analysis. 
 
4.2.9 Agarose electrophoresis 
 
DNA fragments and PCR products were analyzed by agarose gel electrophoresis. Broad 
range agarose was dissolved in TAE buffer by heating. 0.1 µg/mL ethidium bromide 
was added to the liquid agarose before it was casted into an electrophoresis tray. The 
density of the gel used was dependent on the expected DNA size. Fragments of 
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50-200 bp of size were analyzed in a 2 % (w/v) agarose gel and fragments larger than 
200 bp in a 1 % (w/v) agarose gel. The samples were loaded with 1x agarose gel sample 
buffer and separated by electrophoresis at 50-80 V. For imaging the DNA was 
visualized on a UV table at 254 nm, for DNA preparation it was visualized at 365 nm. 
The fragment sizes were compared to molecular weight calibrators. 
 
4.2.10 DNA extraction from agarose gels 
 
The targeted DNA fragment was sliced from the agarose gel by a sharp and clean 
scalpel and extracted by QIAquick Gel Extraction Kit according to the manufacturer’s 
instructions. The DNA was eluted in 30-50 µL EB buffer and stored at -20 °C. 
 
4.2.11 Sequencing and sequence analysis 
 
DNA sequencing was performed by SeqLab Sequence Laboratories in Göttingen. DNA 
amounts were prepared as suggested by the service provider. DNA and protein sequence 
analysis was performed using Vector NTI Suite software provided by Invitrogen, 
Karlsruhe. 
 
4.2.12 Northern blot 
 
Northern blot analysis is based on the identification of target RNA by hybridization 
with a specific reverse complementary DNA probe. This method was performed 
according to standard procedures [Ausubel, et al., 2004]. Ten microgram of RNA was 
separated on a 1.2 % (w/v) agarose gel containing 10 % (v/v) formaldehyde and 
buffer NB. The RNA was transferred with 10x SSC buffer on Hybond-N uncharged 
nylon membrane and baked 20 min at 80 °C prior to probing. 
 
The probe was generated by EcoRI and NcoI digestion of a HBV genome (subtype ayw, 
genotype D), which was labeled with [α-32P]dATP using NEBlot kit according to the 
instructions of the manufacturer. 
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4.2.13 Southern blot 
 
Southern blot analysis is based on the identification of target DNA by hybridization 
with a specific reverse complementary DNA probe. This method was performed 
according to standard procedures [Ausubel, et al., 2004]. The DNA was separated on 
1.2 % (w/v) agarose gel and transferred onto Hybond-N uncharged nylon membrane 
with buffer SB. Prior to DNA transfer, the gel was treated for 15 min with 0.25 M 
hydrochloric acid to destroy the purine bases within the DNA. The membrane was 
baked for 20 min at 80 °C and probed with the same radioactively labeled DNA probe 
described in chapter 4.2.12. 
 
4.2.14 Endogenous Polymerase Assay (EPA) 
 
This assay is based on the detection of a radioactive tracer incorporated into the HBV 
genome by the encapsidated viral polymerase. 3x105 huh-7 cells were seeded in 6-well 
plates and transfected with 2 µg HBV DNA using Fugene 6. The enveloped viral 
particles were precipitated from the cell culture supernatant 5 d after transfection using 
a HBsAg-specific antibody (a kind gift from Klaus-H. Heermann, University of 
Goettingen, Dept. Virology, Germany) and swollen protein-A sepharose beads. The 
EPA reaction was performed as described [Koschel, et al., 2000] using 10 µCi [α-
32P] dCTP for the labeling. The labeled DNA was separated by 1 % (w/v) agarose gel 
electrophoresis without ethidium bromide. The radioactive gel was dried in a vacuum 
dryer and analyzed by autoradiography. 
 
4.3 Cell lysis 
 
4.3.1 Enzymatic cell lysis 
 
A bacterial cell pellet (2-4 g wet mass) was suspended in 30 mL TBS buffer containing 
a spatula tip lysozyme and protease inhibitors in effective concentrations (Tab. 7). The 
suspension was agitated for 20 min at room temperature and sonicated on ice for three 
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intervals of 50 watts intensity. The lysate was cleared by ultracentrifugation at 
76,000x g for 1 h at 4 °C. 
 
4.3.2 Cell lysis using detergent 
 
Confluent adherent liver cells on a 6 cm cell culture dish were washed twice in PBS and 
lysed on ice in 500 µL low detergent lysis buffer (0.2 % (v/v) NP-40, 20 mM Tris, 
150 mM sodium chloride, 1 mM EDTA, pH 7.5 and protease inhibitors at effective 
concentrations (Tab. 7)) or in 500 µL high detergent lysis buffer (RIPA; 20 mM Tris, 
1 % (w/v) sodium deoxycholate, 1 % (v/v) Triton X-100, 0.1 % (w/v) sodium dodecyl 
sulfate, 150 mM NaCl, pH 7.2). The lysed cells were collected by a rubber policeman 
and cleared by ultracentrifugation at 76,000x g for 10 min at 4 °C. 
 
4.3.3 French Press 
 
A pellet of 2-4 g (wet weight) prokaryotic or eukaryotic cells was suspended in 30 mL 
TBS containing protease inhibitors in effective concentrations (Tab. 7). The suspension 
was cooled at 4 °C and disrupted at 20,000 psi differential pressure in a French Press. 
The disruption was repeated three times before the lysate was cleared by 
ultracentrifugation at 76,000x g for 1 h at 4 °C. 
 
METHODS 
58 
4.4 Protein chemistry 
 
4.4.1 Protein quantification 
 
4.4.1.1 Optical density 
 
The amino acids tryptophan and tyrosine absorb light at a wavelength of 280 nm. Due 
to variable amino acid composition the absorption of 1 mg protein/mL is between 0.5-2 
absorption units (AU). The molecular extinction coefficient of TP (35,800 L x mol-1 x 
cm-1) and the S domain (25,800 L x mol-1 x cm-1) was calculated by evaluation of the 
amino acid sequence using Vector NTI. Based on this calculation 1 AU equates 0.63 mg 
TP domain/mL or 0.73 mg S domain/mL, respectively. 
 
4.4.1.2 Bradford assay 
 
The binding of proteins to the dye Coomassie Brilliant Blue G-250 in the Bradford 
reagent stabilizes the anionic form of the dye. This shifts the light absorption maximum 
from 465 nm to 595 nm. Protein quantification was performed according to the 
manufacturer’s instructions. 
 
4.4.2 SDS-PAGE electrophoresis 
 
This method separates a protein mixture dependent on its molecular weight (MW) 
composition. It was performed as described in standard protocols [Ausubel, et al., 
2004]. The polymer density of the separation gel depends on the expected MW of the 
target protein (MW<30 kDa = 15 % (w/v) PAGE gel, MW >30 kDa = 10 % (w/v) 
PAGE gel). Proteins are denaturated in SDS-PAGE sample buffer by 5 min heat 
denaturation at 95 °C prior to electrophoresis in SDS-PAGE buffer at 80-120 V. 
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4.4.3 Silver staining 
 
This technique visualizes protein bands in a PAGE gel. It is based on the specific redox 
potential of proteins that is sufficient to reduce silver ions to its amorphous metallic 
state. The PAGE gel was incubated for 20 min in 50 mL of buffer SFi and SKo, washed 
3x 10 min in deionized water and subsequently incubated for 20 min in 50 mL of buffer 
SKe. The PAGE gel was developed in 50 mL buffer SE and the reaction was stopped by 
~2 mL glacial acetic acid when the protein bands appeared in a proper resolution 
compared to the background staining. The gel was digitalized using a regular flat bed 
scanner. 
 
4.4.4 Western blot 
 
Separated proteins in a SDS-PAGE gel were transferred on a methanol pretreated PVDF 
membrane (Hybond-P) using a semi-dry blotting chamber as described in Fig. 12. The 
proteins migrate from the gel onto the membrane in an electric field of 1.3 mA/cm² for 
1 h. Free membrane surface was coated using blocking solution (10 % (w/v) skim milk 
powder in buffer PBS-T). Antibodies were diluted in blocking solution as suggested by 
the manufacturer. Unbound antibodies were removed by washing with buffer PBS-T. 
For detection the membrane was incubated with peroxidase substrate reagent (ECL) as 
described by the manufacturerand exposured to a scientific imaging film. 
 
 
Figure 12: Scheme of a semi-dry blotting stack. Blotting paper (BP) in the size 
of the SDS-PAGE gel were soaked with anode I (light grey) /II (dark grey) or 
cathode buffer (red) and piled together with a PVDF membrane (green) and the gel 
(blue) to a semi-dry blotting sandwich in the order as indicated. The stack is held 
by the anode (bottom) and the cathode (top). Within 1 h and 1.3 mA/cm² the 
proteins migrate towards the anode onto the PVDF membrane. 
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4.4.5 Immuno-histology 
 
Intracellular localization of proteins was determined by immuno-staining of 
permeabilized cells by fluorescence labeled antibodies. Eukaryotic cells were cultivated 
on a 15 mm glass cover slip in a 3.5 cm² cell culture dish. The cells were fixated for 
15 min in -20 °C cold 100 % (v/v) ethanol including DAPI. All subsequent incubation 
steps were performed light protected at room temperature with slight agitation. The cell 
membrane was permeabilized by buffer PBS-T and the free surface was coated using 
blocking solution (10 % (w/v) bovine serum albumin in PBS-T). The primary and 
secundary antibodies were diluted in blocking solution as suggested by the 
manufacturer. Unbound antibodies were removed by washing with buffer PBS-T and 
the coverslip was sealed in mounting medium on a microscope slide. Slides were stored 
light protected at 4 °C prior to analysis in a confocal laser scanning microscope. 
 
4.4.6 In vitro phosphorylation 
 
E. coli produced terminal protein domain was dialysed (cut off 10,000 kDa) against 1x 
buffer K. The kinase reaction was initiated by addition of 10 µCi [γ-32P] ATP and of 
5-10 U of rat brain PKC (catalytical subunit) or recombinant human CKII, both 
purchased from Calbiochem. After 30 min incubation at 30 °C the reaction was stopped 
by addition of SDS-PAGE sample buffer and heat treatment (5 min, 95 °C). Proteins 
were separated by 12 % (v/v) SDS-PAGE, the gel was dried and incorporated radiation 
was detected by autoradiography. 
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4.5 Microscopy 
 
4.5.1 Confocal laser scanning microscopy 
 
Fluorescent labeled cells were analysed with a confocal laser scanning microscope. 
With this method the excitation of various fluorescence dyes can be focused to a 
defined layer within a cell. This offers the possibility to resolve a cell’s fluorescence in 
a precise three-dimensional image and to investigate the co-localization of proteins 
within a cell. The analysis was performed using an Axioplan LSM-510 microscope. 
 
4.5.2 Electron microscopy 
 
HepG2.2.15 cells on Cytodex-3 were treated with 2.5 % (v/v) glutaraldehyde in 
50 mmol/L Hepes buffer. After a brief washing step with deionized water the carriers 
were fixated with 1 % (w/v) osmium tetroxide for 1 h. Water was removed by washing 
with an increasing gradient of ethanol. The samples were dried by carbon dioxide using 
CPB-303 Critical Point Dryer. Finally, the samples were coated with a 10 nm layer of 
gold by a sputter coater and analyzed at 5 kV by a LEO 1530 field emission scanning 
electron microscope. 
 
4.6 Antibody generation 
 
E. coli derived antigen were purified under denaturated conditions and dialyzed against 
50 mM Tris buffer at pH 9. Under these conditions the antigens precipitated during 
dialysis due to their weak solubility close to the isoelectric point. Prior to injection, 
about 1 mg of precipitated antigen was suspended in 0.5 mL PBS and emulsified with 
0.5 mL of Freunds adjuvant through a 20 gauge injection needle (Fig. 13).  
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Figure 13: Generation of an antigen-adjuvant emulsion. The PBS/antigen suspension and the 
hydrophobic adjuvant were emulsified by a repeating passage through a 20 gauge injection 
needle, which empties in a syringe at both ends. 
 
The injections were placed subcutaneously at three different sites near the lymph nodes 
of a rabbit. A typical immunization is summarized in Tab. 9. About two weeks after the 
last boost injection the rabbit was sacrificed. The blood serum was derived by 
centrifugation after coagulation at room temperature. The serum was stored at -20 °C 
until affinity purification. 
 
Table 9: Typical time course for the immunization of rabbits. Incomplete 
Freunds adjuvant consists of mineral oil and an emulsifier substance like lanoline; 
complete Freunds adjuvant contains heat-inactivated Mycobacterium tuberculosis, 
additionally. 
Injection Time Antigen Adjuvant
1st day 1 ~1 mg Freunds complete
2nd 2 weeks ~1 mg Freunds incomplete
3rd 1-2 month ~1 mg Freunds incomplete
 
 
4.7 Protein purification 
 
All chromatographic protein purification methods were performed using the Äkta 
Purifier design. 
 
4.7.1 Nickel-chelating chromatography 
 
Recombinant proteins were expressed with a terminal extension of six histidine residues 
in a row. At pH >6.0 this (His)6-tag specifically binds nickel ions, which are 
immobilized by crosslinked nitrilotriacetic acid (NTA) to a gel matrix (Fig. 14). 
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Figure 14: Purification principle of nickel-chelating chromatography. Terminal histidine 
extensions of a recombinant protein (blue) form a complex with nickel ions and immobilized 
nitrilotriacetic acid (red) at pH >6. Figure from Qiagen Expressionist. 
 
The bound proteins can be eluted by addition of EDTA, a pH shift <6.0 or an excess of 
side chain analogue imidazole. The soluble (His)6-tagged polymerase domains were 
extracted from 2-4 g of wet bacterial biomass. The cells were disrupted by a French 
Press and cleared by ultracentrifugation (4.3.3). The supernatant was diluted in buffer 
AN to 50 mL and subjected to 1 mL column volume (cv) nickel-NTA sepharose. The 
column was washed for 10 cv with buffer WN and proteins were eluted by buffer EN. 
Fractions were examined by Western blot and the target protein was pooled and 
concentrated by ultrafiltration. The molecular weight cut off (MWCO) of the 
ultrafiltration unit was set to half of the molecular weight of the target protein. 
 
Insoluble intracellular proteins were purified by denaturing nickel-NTA purification. 
The ultracentrifugation pellet after the cell disruption step was solved in 30 mL of 
chaotropic lysis buffer LG by stirring gently for 1 h at room temperature. Occasionally, 
the suspension was homogenized through a 20-gauge injection needle. The suspension 
was cleared by ultracentrifugation (76,000x g, 1 h), diluted to 50 mL in buffer AD and 
subjected to 1 mL nickel-NTA sepharose. The column was washed for 10 cv in buffer 
WD and eluted in buffer ED. The fractions containing target protein were pooled and 
further purified by cationic exchange chromatography. 
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4.7.2 Cationic exchange chromatography 
 
This method separates a complex protein mixture due to net charge variation at a 
distinct pH. The denaturated and prepurified recombinant polymerase domain was 
diluted to 50 mL with buffer AMS and subjected to a MonoS cationic exchange column 
at pH 5.5. The bound proteins were separated by elution with a linear gradient of 20 cv 
to buffer AMS including 1 M sodium chloride. 
 
4.7.3 Gel filtration 
 
Gel filtration columns separate molecules due to molecular weight differences. Defined 
pore sizes in the gel matrix increases the retention time for smaller molecules due to an 
increased molecule diffusion into the matrix. Bigger molecules pass the matrix faster 
and elute first. This method was used for the desalting of ammonium sulfate 
precipitated proteins. Therefore, a HiTrap Desalting gel filtration column with a cv of 
5 mL was equilibrated with PBS or TBS buffer. 0.5 mL of a protein-salt mixture was 
injected and the early protein peak was separated from the late salt peak. 
 
4.7.4 Ammonium sulfate precipitation 
 
Soluble proteins were precipitated with solid ammonium sulfate (APPENDIX 2). The 
fine powder was added slowly to the gently agitated sample. The performed protein 
precipitation and the subsequent washing and centrifugation steps were performed at 
room temperature. When the targeted salt concentration was reached the sample was 
incubated for an additional 30 min and the precipitated proteins were removed by 
centrifugation at 10,000x g for 30 min. The protein pellet was washed twice with an 
ammonium sulfate solution with the same salt concentration as the proteins that were 
precipitated. The pellets were stored at 4 °C. 
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4.7.5 Antibody affinity purification 
 
The generated polyclonal rabbit sera directed against the TP domain and the S domain 
of the HBV P protein were purified by antigen affinity chromatography. The affinity 
matrix was generated by N-hydroxysuccinimide (NHS)-activated sepharose, which 
covalently binds amino groups. The immobilization of denaturated antigen was 
performed with variations to the instructions of the manufacturer as described below: 
 
The purified antigen was dialyzed in PBS buffer at pH 8. Tris buffer would disturb the 
subsequent coupling reaction. About 1.5 mg of antigen precipitate was solved in 1 mL 
NHS-D buffer containing DMSO and the protein concentration was determined 
spectrophotometrically at 280 nm. Immediately before the coupling reaction ~2 mL of 
NHS-activated sepharose was prewashed by ~8 mL NHS-D buffer and added to the 
antigen solution. The suspension was incubated at room temperature with gentle 
agitation overnight. After that the suspension was separated by 500x g centrifugation, 
washed three times with 1 mL NHS-D and the supernatants were pooled for protein 
quantification. The remaining active NHS groups of the antigen-sepharose were 
inactivated by alternated washing with buffer NHS-A and NHS-B as described by the 
manufacturer. 
 
The supernatants were pooled and mixed 1:2 with buffer NHS-G. The coupling 
efficiency for TP and S immobilization was calculated as described in (1). 
 
(1) Coupling efficiency (%) = (A-B)/A * 100 
 A = optical density at 280 nm (antigen solution) * volume (antigen solution) 
 B = optical density at 280 nm (supernatant pool) * volume (supernatant pool) 
 
10-13 mL rabbit blood serum was cleared by 0.45 µm filtration and the pH was adjusted 
to pH 8 with 100 mM Tris buffer. The immunoglobulin content was enriched by 
fractionated precipitation in the 20-50 % (w/v) ammonium sulfate faction. The 
antibody-salt pellet was solved in 800 µL PBS and desalted by gel filtration. The 
antigen-affinity matrix was packed in an empty chromatography column and 
subsequently washed with 2 cv PBS, 3 cv buffer EAB and equilibrated by 10 cv PBS. 
The desalted immunoglobulin fraction was diluted 1:1 in PBS and subjected to the 
METHODS 
66 
affinity column. Unspecific antibodies were removed by washing for 10 cv with PBS. 
The antigen-antibody binding was dissociated at pH 2.3 by a 5 cv step gradient with 
buffer EAB. To prevent denaturation of the antibodies the pH was immediately 
neutralized by providing 20 % (v/v) 0.5 M potassium phosphate buffer (pH 8) to each 
fraction. The antibody fractions were pooled, concentrated by ultrafiltration and stored 
at -20 °C in 50 % (v/v) glycerol. 
 
4.7.6 TP binding partner fishing 
 
Recombinant terminal protein domain was purified and polished to injection grade as 
described in 4.7.1-2. The TP containing fraction of the cationic exchange run was 
adjusted to pH 8 and the protein content was quantified at 280 nm. 
2 mL Ni-NTA agarose suspension was washed with 10 mL buffer ATP and suspended in 
the TP domain solution. The sample was gently agitated for 1 h at room temperature. 
The agarose was washed twice with 1 mL buffer ATP, the supernatants were pooled and 
the protein content was measured at 280 nm. The coupling efficiency was ~90 % as 
calculated similar to (1). 
 
Same amounts of TP-agarose were loaded in two empty chromatographic columns and 
one column was loaded with an equal amount of ‘empty’ Ni-NTA Superflow (Fig. 15). 
The denatured TP was refolded by a slow linear gradient for 30 cv to buffer R. All three 
columns were equilibrated for 10 cv with CKII buffer. The same volume was injected 
into every column. Every injection contained 200 µM GTP, the injection for the TP* 
column contained an additional 2,500 U protein kinase CKII (Fig. 15). The columns 
were sealed and incubated for 3 h at 27 °C and washed with 5 cv CKII buffer. 
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Figure 15: Immobilization and subsequent in vitro phosphorylation 
of TP domain on Ni-NTA Superflow. Same amounts of each reagent 
were applied to the (+) indicated columns: Terminal Protein domain of 
the HBV polymerase (TP domain), 200 µM GTP, 2,500 U protein 
kinase CKII. 
 
The huh-7 cell proteins were extracted from 1050 cm² confluent grown huh-7 by 
sonication in TBS buffer, including protease inhibitors and 1 mM EDTA. The soluble 
fraction of the cell lysate was cleared by centrifugation at 76,000x g, filtered through a 
0.45 µm membrane and adjusted to pH 8 with 100 mM Tris buffer. The protein content 
was precipitated with 75 % (w/v) ammonium sulfate according to chapter 4.7.4, washed 
with 75 % (w/v) ammonium sulfate solution and divided in 6 protein pellets. Each pellet 
was solved in 400 µL TBS buffer and incubated for 15 min at room temperature and 
800 rotations per minute (rpm). The protein solution was cleared by centrifugation 
(16,000x g, 15 min, and 4 °C) and desalted with TBS as described in chapter 4.7.3. The 
protein peak was pooled and diluted with 50 mL buffer ABP, mixed and distributed 
evenly onto the three columns. Unbound sample was removed by washing with 5 cv 
buffer ABP and binding partners were eluted with buffer ABP including 1 M sodium 
chloride. The eluted fractions were stored at -80 °C. 
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5 RESULTS 
 
5.1 Cultivation of HepG2.2.15 on Cytodex-3 
 
5.1.1 Identification of the optimal cell density 
 
Culture conditions for cultivation of HepG2.2.15 on Cytodex-3 were optimized in a 
culture volume of 10 mL including 50 mg dry weight (dw) of equilibrated Cytodex-3. 
Initial densities between 1x105 cells/mL and 1x106 cells/mL were evaluated for cell 
attachment and virus secretion 48 h post inoculation. If the number of cells used for 
inoculation was in the range of 3-9x105 cells/mL, a logarithmic correlation between the 
amount of inoculated cells and the level of extracellular HBV genome was observed 
(Fig. 16). Light and electron microscopy showed a negligible attachment of HepG2.2.15 
for all cell densities below 1x105 cells/mL (Fig. 16*) and a good attachment above 
initial 5x105 cells/mL (Fig. 16**). The highest virus secretion after 48 h was observed 
at 9x105 inoculated cells per mL. At this density, cells and microcarrier formed 
extended three dimensional agglomerates after 48 h which were floating in suspension 
(Fig. 16***). Based on this in further experiments an initial cell density of 
5x105 cells/mL was used because of an ideal cell attachment and growth to about 
70-80 % confluence after 48 h. Moreover, this cell density allows a direct comparison to 
adherent HepG2.2.15 cultivation in T175 cm2 culture flasks. 
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Figure 16: Optimal cell density for HBV production and cell attachment of 
HepG2.2.15 on Cytodex-3 after 48 h. 1-10x105 cells/mL were inoculated in 10 mL culture 
media containing 50 mg (dry weight) Cytodex-3. Extracellular HBV genome was 
quantified by real-time PCR. (*) Light microscopy image of carrier suspension with initial 
1x105 cells/mL after 48 h of cultivation. (**) Raster electron microscopy (REM) image of 
carrier suspension with initial 5x105 cells/mL and (***) REM image of 9x105 cells/mL after 
48 h of cultivation. Each white bar reflects 60 µm of size. The REM images were colored 
by Photoshop CS [Lupberger, et al., 2006]. 
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5.1.2 HBV production and antigen secretion 
 
The HBV production and antigen secretion (HBsAg and HBeAg) was examined in two 
20 mL microcarrier culture batches in comparison to two 20 mL stationary cultures. 
5x105 cells/mL were cultured on 100 mg dw Cytodex-3 compared with the equal 
amount of cells grown in stationary culture flasks (T175 cm²) over 72 h. Each 
experiment was performed in two independent, identical batches and each parameter 
was determined in double. The cultivation on Cytodex microcarrier resulted in a 
significant higher HBeAg (Fig. 17A) and a reduced HBsAg (Fig. 17B) secretion as 
compared to the stationary flask culture. 
In addition to the quantification of secreted viral proteins (HBsAg, HBeAg), the 
production of HBV particles was determined by quantifying the amount of extracellular 
HBV genome equivalents (GE) using real-time PCR (Fig. 17C). 48 h post inoculation 
we observed significantly more GE in the microcarrier cultures than in the stationary 
cultures. Under these conditions HepG2.2.15 secreted up to 18 fold more HBV particles 
as compared to the stationary cultures. Taken these results together in the Cytodex-3 
cultures less HBsAg is secreted per extracellular HBV genome than in stationary 
cultures. These data indicate that the cultivation of HepG2.2.15 on microcarrier results 
(i) in an up to 18 fold increased amount of secreted viral particles and (ii) in a 
significantly increased ratio of secreted viral particles to subviral particles. 
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Figure 17: Comparison of HepG2.2.15 virus production on Cytodex-3 (dark bars) 
versus stationary culture flask (striped bars) over 72 h. Every 24 h the half of 
consumed culture medium was replaced. Aliquots of the replaced media were cleared 
and semi-quantified by ELISA for HBeAg (A) and HBsAg (B) and expressed as light 
absorption at 450 nm and 435 nm, respectively. In parallel, extracellular, encapsidated 
viral DNA was prepared and quantified by real-time PCR (C). Error bars were 
calculated as mean value/standard deviation. Differences between production levels 
were significant as assessed by Students t-test (p<0.05) [Lupberger, et al., 2006]. 
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To analyze whether the difference in the amount of secreted viral particles just reflects 
different numbers of cells the total amount of cells was estimated by Western blot 
analysis of cellular lysates using an actin-specific antiserum (Fig. 18). The Western blot 
reveals that in case of the carriers a significant smaller amount of cells produces 
obviously a higher amount of viral particles as compared to the cells grown in flasks. To 
investigate whether the different culture conditions affect the differentiation of the 
HepG2 cells the membrane was reprobed using an alpha-fetoprotein specific serum 
(Fig. 18). The Western blot shows that comparable amounts of the differentiation 
marker alpha-fetoprotein are produced in cells grown on carriers as compared to cells 
grown on flasks. 
 
 
Figure 18: Analysis of cell number and cell differentiation of HepG2.2.15 cells 
grown on microcarrier or stationary culture. Identical amounts of cells (1x107) were 
used for inoculation of microcarrier and stationary flask culture. After 24 h, 48 h, 72 h 
and 96 h cells were harvested and lysed in identical volumes. Samples were analyzed by 
Western blotting using an actin-specific antiserum to evaluate relatively the amount of 
cells and using an alpha-fetoprotein-specific serum to analyze the differentiation state of 
the cells [Lupberger, et al., 2006]. 
 
5.1.3 Virus infectivity 
 
The data described above indicate that cultivation of HepG2.2.15 cells on microcarrier 
results in an elevated amount of virus-specific DNA in the cell culture medium. To 
demonstrate that this increased amount of virus specific DNA is represented by 
complete viral genomes, DNA was isolated from the supernatant taken after 48 h and 
analyzed by Southern blotting (Fig. 19A). The Southern blot verifies that significant 
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higher amounts of viral genomes are found in the supernatant of cells grown on 
microcarrier as compared to the cultivation in flasks. 
To exclude that this is due to an increased secretion of naked capsids the supernatants 
were adjusted to identical amounts of viral genomes and subjected to immuno-
precipitation using an excess of HBsAg-specific serum (Fig. 19B). The quantitative 
PCR analysis of the precipitates demonstrates that the ratio of enveloped capsids to 
naked capsids is not affected if HepG2.2.15 cells were grown in flasks or on 
microcarrier. 
To demonstrate unequivocally that the cultivation of HepG2.2.15 cells on microcarrier 
results in an increased number of infectious viral particles secreted into the supernatant 
identical volumes of supernatant from flasks and microcarrier were concentrated and 
applied for infection of primary Tupaia hepatocytes. Analysis of the HBeAg secretion 
of the infected Tupaia cells shows the significant higher infectivity of the supernatant in 
case of HepG2.2.15 cells grown on microcarrier as compared to cells grown in flasks 
(Fig. 19C). These experiments demonstrate that cultivation of HepG2.2.15 cells on 
microcarrier significantly improves the production of infectious viral particles. To 
investigate whether this is due to a change in the ratio between genomic and 
subgenomic RNA population identical amounts of RNA isolated from the two culture 
systems were analyzed by Northern blotting (Fig. 19D). The Northern blot shows that 
the different cultivation conditions do not affect the ratio between the genomic and 
subgenomic RNA populations. 
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Figure 19: Comparative quantification of viral particles secreted from HepG2.2.15 
grown on microcarrier and in stationary culture. (A) Southern blot analysis of DNA 
isolated from the supernatant of HepG2.2.15 cells grown for 48 h on microcarrier or in 
stationary culture. (B) Supernatants obtained after 72 h cultivation on microcarrier or in flasks 
were adjusted to identical genome equivalents as determined by quantitative PCR. The 
supernatants were subjected to immuno-precipitation using an excess of a HBsAg-specific 
serum (Dako; goat-derived anti-HBsAg) and the amount of precipitated genomes were 
determined by quantitative PCR. (C) Primary Tupaia hepatocytes were infected with 
concentrated supernatant obtained from the microcarrier or flask culture. To quantify the 
infectivity 96 h and 8 d post infection HBeAg secretion was quantified by ELISA. (D) 72 h 
after inoculation total RNA was isolated from HepG2.2.15 cells grown on microcarrier or in 
flasks. The RNA was adjusted to identical concentrations and analyzed by Northern blotting 
using a HBV-specific probe. The left panel shows the methylene blue staining of the 
membrane, indicating that comparable amounts of RNA were loaded. The right panel shows 
that the different culture conditions do not affect significantly the ratio between the different 
HBV-specific RNA species [Lupberger, et al., 2006]. 
 
5.1.4 Effect on cellular signaling 
 
Recent reports describe a preference of HBV to replicate in quiescent cells [Friedrich, et 
al., 2005] and a dependence of HBV replication on the functionality of the  
c-Raf/MEK/ERK signaling cascade [Stockl, et al., 2003]. 
Cell proliferation was analyzed by quantification of proliferating cell nuclear antigen 
(PCNA) expression in HepG2.2.15. Cells grown on microcarrier and in T175 cm² flasks 
were lysed 72 h post inoculation and analyzed by Western blotting (Fig. 20). To control 
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the effect of cell proliferation on PCNA expression the fetal calf serum concentration in 
the culture medium of a parallel batch was shifted from 10 % to 5 %. All samples were 
normalized to intracellular beta-actin expression. The lower PCNA expression in the 
serum deprived cells reflected the decreased cell proliferation. But no significant 
difference of PCNA expression was observed between the two culture systems. This 
experiment showed that the increased HBV production of HepG2.2.15 cells cultivated 
on Cytodex-3 is not due to a decreased cell proliferation. 
A potential activation of the c-Raf/MEK/ERK signaling pathway was examined by 
Western blot analysis using an anti-active MAP-specific antiserum (Fig. 20). The blot 
revealed an obvious higher level of the phoshorylated ERK-2 in cells cultivated on 
microcarrier as in those grown as stationary culture. The tendency of this finding was 
independent from the serum concentration in the culture medium. 
 
 
Figure 20: Comparison of cell proliferation and MAP kinase 
signaling activation in HepG2.2.15 grown on microcarrier versus 
stationary culture. 72 h post inoculation the level of proliferating cell 
nuclear antigen (PCNA) and activated form of extracellular signal-
regulated kinase 2 (P-ERK) was compared in HepG2.2.15 grown on 
Cytodex-3 to cells grown in T175 cm² cell culture flasks by Western 
blotting. In a simultaneous experiment the cell proliferation was limited 
by a reduction of the serum concentration in the culture medium from 
10 % to 5 %. The protein amounts were normalized to beta-actin 
expression [Lupberger, et al., 2006]. 
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5.2 Generation and purification of P directed antibodies 
 
5.2.1 Purification and immobilization of recombinant TP and S domain 
 
The TP domain (amino acid 1-181) and the S domain (amino acid 182-340) of the HBV 
polymerase (subtype ayw) were purified from recombinant bacterial expression systems 
based on the plasmid pJO2 (TP expression vector) and pJO3 (S expression vector). Both 
recombinant domains were produced with an C-terminal (His)6-tag for affinity 
purification by Ni-NTA chromatography. A large amount of high pure protein was 
obtained when the isolation was performed under denaturating conditions (Fig. 21). 
This “injection” grade (Fig. 21, lane MS) was used for antibody generation (4.6), 
antibody affinity purification (4.7.5) and binding partner fishing (4.7.6). 
 
 
Figure 21: Isolation of highly purified terminal protein and spacer domain. M = low 
molecular weight marker, L = crude lysate, P =unsoluble fraction, Ni = after Ni-NTA 
affinity purification, MS =after ionic exchange purification (injection grade). (A) Purified 
21 kDa terminal protein domain. (B) Purified 17 kDa spacer domain. 15 % SDS-PAGE gel 
stained with Coomassie Brilliant Blue G250. 
 
5.2.2 TP and S directed antibody 
 
To generate HBV polymerase specific antibodies rabbits were immunized with 
precipitated injection grade TP domain and S domain, respectively. To minimize 
unspecific adsorption to secondary proteins the rabbit sera were affinity purified using 
the immobilized antigen. The antigen was immobilized to NHS-activated sepharose 
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with a coupling efficiency of about 50 % measured by optical density at 280 nm (1). 
The calculated coupling efficiencies were verified by comparison of the amounts of 
supernatant proteins before and after the coupling reaction (Fig. 22). 
 
 
Figure 22: Coupling efficiency of TP and S domain to NHS-activated 
sepharose. 15 % SDS-PAGE gel stained with protein silver staining. The 
amount of supernatant protein was compared before (Pre..) and after 
(Post..) coupling to NHS-activated sepharose. Estimated 50 % of the TP 
domain (A) and of the S domain (B) immobilized to the sepharose. 
 
Specificity and sensitivity of the purified antibodies were checked by Western blotting. 
Thereto the recombinant antigen (Fig. 21, lane MS) was diluted in equal amounts of 
liver cell lysate and detected by the respective affinity purified antiserum (Fig. 23). 
 
 
Figure 23: Determination of the sensitivity of the purified TP- and S-specific 
antisera. Proteins were separated on a 12 % SDS-PAGE gel. Recombinant antigen was 
diluted in a huh-7 cell lysate background and detected by (A) rabbit α-Pol(TP)2 (B) rabbit 
α-Pol(S)1. The detection level was about 6 ng of TP antigen and 2 ng of S antigen. Both 
antibodies were diluted 1:5000 in 10 % (w/v) skim milk powder in buffer PBS-T. 
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The antibodies generated against the TP domain and the S domain of the HBV 
polymerase did not show any cross reactivity with liver cell proteins because in this 
case bands would be visible in every sample with the same intensity. The TP domain 
derived rabbit α-Pol(TP)2 antibody was able to detect 6 ng of antigen in the cell lysate 
background (Fig. 23A). The S domain derived rabbit α-Pol(S)1 antibody was able to 
detect at least 2 ng of antigen in a cell lysate background (Fig. 23B). The antibodies 
could be diluted 1:8000 in 10 % (w/v) skim milk powder / PBS-T buffer without a loss 
of sensitivity. 
 
The α-Pol(S)1 antibody immuno-precipitated HBV P protein from transfected huh-7 
cells (Fig. 24), whereas the α-Pol(TP)2 antiserum failed to precipitate the polymerase, 
significantly (Fig. 24). 
 
 
Figure 24: Immuno-precipitation of HBV P protein by the generated 
antibodies. Huh-7 cells were transfected with pcDNA3.1 (mock) and its 
descendent pJO13 (P), which codes a CMV promoter driven version of 
HBV P protein. Transfected cells on a 6 cm cell culture dish were lysed in 
0.75x RIPA buffer and precipitated with 30 µL protein A/G agarose beads 
and 3 µL rabbit α-Pol(TP)2 and rabbit α-Pol(S)1, respectively. All 
precipitates were detected with antibody mouse α-Pol(3552). 
 
The aptitude of the purified antibodies for immuno-histology analysis was evaluated by 
detecting of HBV polymerase (i) in baculovirus (AcNPV::HBV P) infected Sf9 insect 
cells (Fig. 25) and (ii) in P protein producing huh-7 cells (Fig. 26). Both antibodies 
detected HBV polymerase in ethanol fixated Sf9 and huh-7 cells. But the rabbit α-
Pol(S)1 showed a higher sensitivity by visualizing lower P expression levels in 
transfected huh-7 cells. 
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Figure 25: Immuno-fluorescence analysis of HBV P expressing Sf9 cells with purified P 
directed antibodies. Sf9 cells were infected with recombinant baculovirus AcNPV::HBV P 
harboring FLAG-tagged version of the human HBV P protein. After ethanol fixation 
(transmission) the cells were stained for human HBV P protein with α-Pol(TP)2 (upper red panel) 
and α-Pol(S)1 (lower red panel), respectively. The specificity of the generated antisera was 
verified by co-staining with α-FLAG M2 antibody (green panel). All measured wavelengths are 
merged in the yellow panel. The engineered baculovirus was kindly provided by Robert Lanford, 
University of Texas, USA. 
 
 
 
Figure 26: Immuno-fluorescence analysis of HBV P expressing huh-7 cells with purified P 
directed antibodies. Huh-7 cells were infected with HBV polymerase expression construct pJo13. 
After ethanol fixation the cells were stained for human HBV P protein (red) with α-Pol(TP)2 (upper 
panel) and α-Pol(S)1 (lower panel), respectively. The cytoskeleton was stained with phalloidin-FITC 
(green), the nucleus with DAPI (blue), and the chaperone protein Hsp90 with a specific antibody 
(light yellow). All measured wavelengths are merged in the yellow panel. 
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Taken this together two sets of antibodies were generated that are able to detect 
specifically HBV P protein in a hepatoma cell and insect cell background by immuno-
histology. In Western blot experiments the generated rabbit α-Pol(S)1 antibody was at 
least 3 times more sensitive and detected about 2 ng recombinant antigen on a SDS-
PAGE gel. Only the α-Pol(S)1 antibody was able to detect the full length HBV P 
protein and was therefore used as antibody of choice for the further analysis of the HBV 
polymerase. 
 
RESULTS 
81 
5.3 Nuclear import of the HBV polymerase 
 
5.3.1 Identification of conserved motifs on the HBV polymerase 
 
The primary amino acid sequence of HBV polymerases were aligned to find conserved 
motifs, which might be susceptible for host cell signaling. Therefore, the P protein of 18 
orthohepadna viruses (human HBV genotypes A-H, two rodent hepatitis B viruses) and 
four avihepadna viruses (from Shanghai duck, ross goose, China duck and heron) were 
compared using the Clustal W algorithm (Fig. 27). 
 
 
Figure 27: Sequence alignment of the HBV polymerase (P) from various virus genotypes and 
species. This figure shows amino acid alignment of I50-L109 referred to the sequence of genotype 
D, which was used in this study. Basic amino acids are highlighted in blue and polar (δ+) amino 
acids are highlighted in turquoise. Conserved kinase recognition sites were identified (red) in human 
HBV genotypes at Thr53 (protein kinase PKC: T/S-X-K/R-X; X = any amino acid) and in 
orthohepadnaviridae at Thr100 (protein kinase CKII: T/S-X-X-E/D; X = any amino acid). A 
bipartite nuclear localization signal (black rectangles) was identified in orthohepadnaviridae, which 
is flanking the CKII recognition site by its two basic amino acid clusters. All identified putative 
motifs were not found in the aligned P proteins of the avihepadnaviridae. 
 
Three conserved motifs were identified in the TP domain of the P protein: a putative 
protein kinase PKC recognition site at threonine 53 (amino acid counting referred to 
genotype D) a putative protein kinase CKII recognition site at threonine 100 and a 
putative bipartite nuclear localization signal (NLS) (Fig. 27). The CKII recognition site 
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is flanked by the two basic amino acid clusters K90-K91 and K104-R106 of the NLS. 
The CKII recognition site and the bipartite NLS were found in all orthohepadnaviridae 
but not in avihepadnaviridae whereas the PKC recognition site is only present in human 
HBV viruses. 
 
5.3.2 TP domain is phosphorylated by protein kinases PKC and CKII 
 
To control experimentally whether the predicted phosphorylation sites indeed can be 
phosphorylated by CKII and PKC in vitro phosphorylation was performed. Thereto, 
highly purified recombinant TP domain was treated was treated with either PKC or 
CKII in the precence of [γ-32P]ATP (Fig. 28). To exclude any phosphorylation by 
contaminating kinases the purified TP domain was incubated as described above, but 
the recombinant kinases were omitted (Fig. 28, left lane). As an additional control the 
corresponding fractions of the Ni-NTA affinity chromatography from E. coli 
transformed with the empty expression vector were subjected to in vitro 
phosphorylation (Fig. 28, mock). 
 
 
Figure 28: In vitro phosphorylation of recombinant TP domain by protein kinases CKII 
and PKC. Purified TP domain and mock purified proteins (empty vector products) were 
incubated with [γ-32P] ATP and the protein kinases PKC and CKII. To control auto-
phosphorylation TP domain was incubated with [γ-32P] ATP in absence of a kinase. The protein 
specificity was verified by the TP specific antibody rabbit α-Pol(TP)2 on a separate lane. 
 
Fig. 28 shows a significant specific phosphorylation of the TP domain only if CKII or 
PKC is present. In case of the controls no significant phosphorylation was observed. To 
confirm the identity of the phosphorylated species with the TP domain Western blot 
analysis was performed (Fig. 28, right panel). This indicates that the predicted kinase 
recognition sites on the terminal protein are indeed accessible for phosphorylation. 
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5.3.3 PKC and CKII phosphorylation affect HBV replication 
 
To study the relevance of CKII-dependent phosphorylation of the TP domain for HBV 
lifecycle primary Tupaia hepatocytes were infected with HBV particles (Fig. 29A). Five 
days after infection the hepatocytes were grown for 36 h in the presence of the cell 
permeable small molecular inhibitor DMAT and the virus replication was analyzed by 
Lightcycler PCR for quantification of secreted de novo synthesized viral particles and 
by Southern blotting for detection of intracellular cccDNA. In the HBV infected 
primary hepatocytes the inhibition of CKII during virus infection caused a strong and 
significant reduction of virus replication indicating that the inhibition of the protein 
kinase CKII impairs HBV replication (Fig. 29A). DMAT did not significantly reduce 
cell viability under these conditions, which was analyzed by DAPI staining of the cells 
at the end of the experiment (data not shown). This indicates that integrity of CKII is 
crucial for the infectivity of HBV. 
To control the specificity of the observed effect the constitutively HBV expressing cell 
lines HepG2.2.15 and HepAD38 were instrumental. Both cell line harbor stably 
integrated HBV genomes. Due to the stable integration of the genome the re-import of 
de novo synthesized genomes plays a minor role for maintaining the pool of 
transcriptional templates. Therefore, inhibition of polymerase import should exert a 
small effect. HepG2.2.15 and HepAD38 cells were treated with DMAT and virus 
secretion was quantified by Lightcycler PCR (Fig. 29B). Under these conditions 
inhibition of CKII with DMAT did slightly but not significantly reduce virus secretion 
as compared to the solvent control (Fig. 29B). Differences in virus secretion was 
assessed by Students t-test (p<0.05).  
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Figure 29: Effect of CKII inhibition on HBV secretion of infected hepatocytes. 
(A) Primary Tupaia hepatocytes were infected with HepAD38 derived HBV and five days 
post infection treated for 36 h with solvent DMSO or DMAT (10x IC50). The HBV genome 
secretion was measured by Lightcycler PCR. The cccDNA content of infected Tupaia 
hepatocytes was visualized by Southern blot using a HBV specific probe. (B) After 2 h 
inhibitor pretreatment the stably HBV transfected cell lines HepG2.2.15 and HepAD38 were 
treated overnight with 10x IC50 concentration of CKII inhibitor DMAT (IC50 in rat 
liver = 150nM) and genome secretion was compared to the solvent control DMSO measured 
by Lightcycler PCR. 
 
To investigate the role of PKC for the HBV lifecycle HepG2.2.15 and HepAD38 were 
treated overnight with PKC inhibitor Gö6976. To control weather DMSO exerts a 
stimulatory effect on the HBV replication the inhibitor was diluted in equal amounts of 
DMSO. After a 2 h pretreatment with the Gö6976 same amounts of cells were incubated 
with the PKC inhibitor overnight and virus secretion was measured by Lightcycler PCR. 
In contrast to CKII the inhibition of PKC leaded to a significant increase of HBV 
secretion, which was dose dependent (Fig. 30). This indicates that PKC has an 
inhibitory effect on the HBV lifecycle. 
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Figure 30: Effect of PKC inhibition on HBV secretion of infected hepatocytes. 
After 2 h inhibitor pretreatment the stably HBV transfected cell lines HepG2.2.15 and 
HepAD38 were treated overnight with 2x, 10x, and 100x IC50 concentrations of PKC 
inhibitor Gö6976 (IC50 for PKCα = 2.3 nM) and genome secretion was compared to 
the solvent control DMSO measured by Lightcycler PCR. 
 
A treatment of hepatocytes with small molecule inhibitors can cause a variety of even 
opposite effects. Therefore, to learn more about the relevance of the putative kinase 
sites and the nuclear localization signal for the viral lifecycle, mutated HBV genomes 
were generated and examined for their ability to replicate in huh-7 (Fig. 31). To perform 
site directed mutations, a well characterized 2.5 fold HBV genome [Sells, et al., 1987] 
was truncated to generate a 1.2 fold descendent plasmid with only a single copy of the 
polymerase open reading frame. This genome harbored the minimal requirements for a 
productive viral replication. 
 
To prevent the phosphorylation of a kinase recognition site the relevant threonine was 
substituted by an isoleucine (T53I, T100I). To simulate a phosphorylation the relevant 
threonine was replaced by an aspartate, which simulates the negative charge of a 
phospho-threonine (T53D, T100D). The putative bipartite NLS was inactivated by 
destroying one basic cluster of the motif (K105Q, K106S). 
RESULTS 
86 
A polymerase-deficient HBV genome with an immediate transcriptional terminator 
sequence inserted in the open reading frame of the P protein was used as a control. This 
HBV (ΔP) construct was kindly provided by Dr. Alexander Pairan and Dr. Volker 
Bruss, University of Göttingen, Germany. 
 
 
Figure 31: Effects of the identified motifs on virus replication. After immuno- 
precipitation with a HBsAg specific antibody the 3.2 kb HBV genomes were visualized by 
the radioactive tracer [α-32P]dCTP incorporated by the endogenous polymerase activity. In 
the 1.2 fold HBV wild type genome the unphosphorylated form of the CKII and the PKC 
recognition site in the P protein was simulated by a threonine to isoleucine substitution (Δ). 
The pseudo-phosphorylated kinase recognition site was simulated by a threonine to 
aspartate substitution (∗). The NLS was inactivated by mutating the downstream basic 
cluster (K105Q and K106S) on the P protein. A 2.5x HBV genome and a P deficient 
genome (HBV (ΔP)) served as controls. 
 
The secreted HBV particles were quantified by endogenous polymerase assay (EPA) 
72 h post transfection of the genomes in huh-7 cells (Fig. 31). If a phosphorylation of 
the CKII recognition site on the P protein was prevented a decreased HBV secretion 
was observed (ΔCKII). The virus production was restored at the pseudo-phosphorylated 
CKII recognition site (∗CKII). No significant difference to the wild type genome 
replication was observed if the PKC recognition site was inactivated by isoleucine 
(ΔPKC). But a significant decrease in virus secretion occurred by transfection of the 
corresponding pseudo-phosphorylated mutant (∗PKC). When both kinase recognition 
sites were inactivated (ΔCKII, ΔPKC) the virus secretion was similar to the ΔCKII 
mutant genome. When both kinase recognition sites were pseudo-phosphorylated no 
virus secretion was detected. The NLS deficient mutant did not secrete active viral 
particles. 
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Taken these results together a CKII phosphorylation of the P protein maintains virus 
production and is crucial for virus replication. In contrast the phosphorylation of the 
HBV polymerase by PKC has an inhibitory effect on the virus production. No obvious 
functional connection of both phosphorylation sites was observed due to the dominant 
effect caused by the CKII pseudo-phosphorylation in the double isoleucine mutant. 
 
5.3.4 P protein harbors a functional bipartite NLS, which depends on 
phoshorylation 
 
The sequence analysis localized the CKII-phosphorylation site within a predicted 
bipartite nuclear localization signal (NLS). Based on this the resulting questions are (i) 
whether the predicted NLS indeed displays a NLS function and (ii) whether CKII-
dependent phosphorylation affects the functionality of the TP-domain-derived NLS. 
If the NLS is inactivated in a HBV genome by manipulating the basicity of the 
downstream cluster to K105Q and K106S the HBV genome is not able to replicate in 
huh-7 cells (Fig. 31, ΔNLS mutant). This indicates that the integrity of the putative NLS 
on the P protein is important for the viral lifecycle. 
To study the functionality of the TP-derived putative bipartite NLS huh-7 cells were 
transfected with an expression plasmid encoding for a fusion protein of the putative 
NLS and GFP (NLSPOL-GFP). As a positive control served a 17 aa long prototype NLS 
(K142 to K158) derived from human nucleoplasmin (accession number gi114762) fused 
to the amino terminus of GFP (NLSNP-GFP). The intracellular distribution of the GFP 
fluorescence was quantified by confocal laser scanning microscopy in living cells. 
Compared to wild type GFP expression, which was found even distributed within the 
cell (Fig. 32A), the level of NLSPOL-GFP was ~30 % higher in the nucleus than in the 
cytosol (Fig. 32C). In case of the positive control (NLSNP-GFP) an about 75 % elevated 
level of GFP specific fluorescence in the nucleus was observed (Fig. 32B). This 
confirms that the predicted sequence indeed acts as a functional NLS. To analyze a 
putative relevance of CKII-dependent phosphorylation for the functionality of the TP-
derived NLS, NLSPOL-GFP producing cells were incubated for 2 h with CKII inhibitor 
DMAT prior analysis by confocal microscopy. The quantification of GFP fluorescence 
revealed that presence of the CKII inhibitor prevented the directed nuclear enrichment 
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of the NLSPOL-GFP (Fig. 32D). Taken together these results indicate that the HBV 
polymerase harbors (i) a bipartite nuclear localization signal, (ii) which functionality 
dependents on CKII mediated phosphorylation. 
 
 
 
Figure 32: Subcellular localization of NLS-GFP fusion proteins. Huh-7 cells were transfected with 
(A) the negative control wild type GFP (pEGFP-N1), (B) a positive control: GFP fused to a prototype 
bipartite NLS of human nucleoplasmin, (C) GFP fused to the putative bipartite NLS of HBV P protein, 
(D) the same as (C) but cells were treated with 10x IC50 of CKII inhibitor DMAT 2 h prior analysis. 
The fluorescence was measured in living cells by confocal laser scanning analysis. The central layer 
(out of 6) was quantified along the red indicated line and displayed in the corresponding graph of the 
lower panel as relative fluorescence intensity [I]. Differences of mean fluorescence intensities in the 
cytoplasm and within the nucleus (indicated as black line in the graph) were calculated and are 
indicated in percent. 
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5.3.5 Binding of karyopherin-α2 to TP depends on CKII mediated 
phosphorylation 
 
To verify these results and to characterize the functionality of the putative NLS the 
binding of endogenous PKC, CKII, and karyopherin-α2 to immobilized TP domain was 
investigated. Karyoperin-α2 (formerly known as importin-α2) is a key adaptor protein 
for the directed nuclear import of proteins. Recombinant TP domain was bound to Ni-
NTA columns and in vitro phosphorylated as described in chapter 4.7.6. The soluble 
protein fraction of huh-7 cells was purified by ammonium sulfate precipitation to 
remove endogenous phosphate donors like nucleotide triphosphates and subjected 
evenly to the three columns. Binding partners were eluted by a sodium chloride 
gradient. Elution fractions 2-4 were analyzed by Western blotting (Fig. 33). 
 
 
Figure 33: Binding of karyopherin-α2, PKC, and CKII to immobilized TP domain. 
The interaction of soluble protein fraction of huh-7 cells to immobilized TP domain was 
investigated by Western blotting of the sodium chloride eluted fractions 2-4. Compared to 
the blank column w/o immobilized TP a significant binding of endogenous CKII (central 
panel) and PKC (lower panel) was observed. Karyopherin-α2 bound only to the CKII 
pretreated TP column (upper panel). DP = flow through CKII treated TP column; D = flow 
trough of the untreated TP column. 
 
A significant binding of endogenous protein kinases PKC and CKII to immobilized TP 
was detected compared to the blank column. Karyopherin-α2 bound only to CKII/GTP 
treated TP but not to the blank column and to the GTP treated TP column (Fig. 33). An 
unspecific binding of karyopherin-α2 to residual recombinant CKII from the 
pretreatment can be excluded due to similar amounts of endogenous CKII, which were 
found in the eluted fractions. 
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A binding of karyopherin-α2 to the NLS is a prerequisite for a directed nuclear import. 
This result implies a CKII-phosphorylation dependent nuclear import of the HBV 
polymerase within huh-7 cells. 
 
5.3.6 Ab initio modeling of the TP domain tertiary structure 
 
To calculate the accessibility of the nuclear localization signal in the TP domain of the 
HBV P protein an ab initio modeling was performed based on the ROSETTA protein 
folding program developed by Kim Simons, David Baker, Ingo Rudzinski, and Charles 
Kooperberg [Simons, et al., 1997]. The program cleaves a protein primary sequence 
virtually and calculates the conformations of the small fragments which are assembled 
to the five most probable versions of the tertiary structure of the target protein. It 
captures sequence dependent features of protein structures, such as the burial of 
hydrophobic residues in the core, as well as universal sequence independent features, 
such as the assembly of beta-strands into beta-sheets. 
 
Fig. 34 shows the predicted tertiary structures of the wild type TP domain (T100) 
compared to a pseudo-phosphorylated TP mutant (T100D), where the threonine of the 
CKII recognition site is substituted by an aspartate. In this theoretical model the 
accessibility of the bipartite NLS motif (blue) in the wild type TP is blocked by a large 
beta sheet formed by the upstream part of the sequence (Fig. 34, left model). The 
substitution T100D within the CKII recognition site leads to a conformational change of 
the sequence upstream of the NLS. The consequence is the disclosure of the NLS by the 
protein bar, which causes the exposure of the NLS to the protein surface (Fig. 34, right 
model). In both models the protein primer tyrosine 63 is indicated and located at the 
opposite side of the theoretical model. 
 
This folding pattern was similar in the four alternative tertiary structures predicted by 
ROSETTA. They differed only in minor folding variations (data not shown). 
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Figure 34: Ab initio modeling of TP domain (amino acid 1-181). Three dimensional models of wild 
type TP domain (T100, left panel) and a T100D CKII pseudo-phosphorylated version (T100D, right 
panel) were calculated using ROSETTA [Simons, et al., 1997]. The calculated PDB coordinates were 
visualized using PyMol. The amino acids of the bipartite NLS are highlighted in blue, the tyrosine-
genome priming site Y63, the putative PKC recognition site T53 and the CKII recognition site T100 are 
highlighted in yellow. The amino acid spacer between the two NLS cluster are highlighted in red. The N-
terminal (N’) and the C-terminal (C’) ends of the models are indicated. 
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6 DISCUSSION 
 
An effective vaccine to prevent hepatitis B virus infection has been available since 
1986, however HBV remains a major health problem with an estimated 400 million 
chronic infections worldwide [Hollinger and Liang, 2001]. HBV is a major causative 
agent for hepatocellular carcinoma, and perinatally infected children have an especially 
high risk of developing chronic HBV [de Franchis, et al., 2003]. In some highly 
endemic regions including China, Senegal, and Thailand the HBV infection rates in 
infants exceeds 25 % [Hollinger and Liang, 2001]. Currently, chronic HBV infections 
are treated with pegylated interferon-alpha in combination with nucleoside/nucleotide 
analogs [Buster and Janssen, 2006]. In the majority of cases this treatment suppresses 
the viral replication successfully, but there is a very low cure rate for chronical HBV 
infection. Another problem is the appearance of HBV escape mutants that are resistant 
to nucleos(t)ide-analogs after long term treatment. This emphasizes the need for 
additional therapy strategies to increase the success rate of the current chronic HBV 
treatments [Buster and Janssen, 2006]. 
 
Important parts of the viral lifecycle that could be potential targets for new antiviral 
drugs have yet to be fully characterized. For example, the viral surface proteins mediate 
binding of HBV to the hepatocyte, but the receptor complex that binds to the surface 
proteins is not known. Another poorly understood part of the viral lifecycle is the 
mechanism leading to the formation and amplification of viral cccDNA in the host cell 
nucleus. The stability and persistence of this episomal viral DNA during antiviral 
treatment remains an unsolved problem. 
 
6.1 Cultivation of HepG2.2.15 on microcarrier increases HBV 
replication 
 
Until recently, no adequate infection model for HBV was available. In 2001 Josef Kock 
and co-workers established a heterologous infection model that allows the study of 
HBV infection in primary hepatocytes of Tupaia belangeri [Kock, et al., 2001]. Primary 
hepatocytes are obtained by liver perfusion from the animals and can be efficiently 
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infected with human HBV. A few days post infection, de novo synthesized infectious 
viral particles are secreted and cccDNA is detectable within the Tupaia cells. Another 
novel HBV infection model was described by Philipe Gripon and co-workers in 2002 
[Gripon, et al., 2002]. The highly differentiated hepatoma cell line HepRG appears to be 
susceptible to HBV infection when cultivated in the presence of corticoids and dimethyl 
sulfoxide. These new experimental systems require large amounts of infectious human 
HBV with a defined genome. The stably transfected cell line HepG2.2.15 serves as an 
HBV production system in vitro and is usually grown two-dimensionally under 
stationary conditions in a culture flask [Ganem, 1991]. Studies with various virus 
infected cell lines have shown that a variation of the cultivation substrate can alter virus 
replication and secretion [Wu and Huang, 2002; Wu, et al., 2002]. 
 
One aim of this study was to optimize HBV production by cultivation of the 
HepG2.2.15 cell line on the spherical microsubstrate, Cytodex-3, and to characterize the 
effects of this cultivation method on cellular signaling. To study this, equal amounts of 
HepG2.2.15 cells were cultivated on Cytodex-3 in suspension and compared to 
conventional cultivation in a T175 cm² flask. HBV production and viral protein 
secretion from the cells were compared. In these experiments a significantly higher 
level of secreted HBeAg was observed in the microcarrier cultures than in the stationary 
cultures (Fig. 17A). In accordance with this, an 18 fold higher HBV production in the 
microcarrier cultures was observed 48 h post inoculation by quantification of HBV 
genomes in the cell culture supernatants (Fig. 17C). The stationary cultures secreted 
significantly more HBsAg into the medium (Fig. 17B). 24 h post inoculation the HBsAg 
secretion was 13 % higher and after 72 h was 35 % higher than in the suspension 
cultures. When correlated with the extracellular genome equivalents, the data from the 
immuno-precipitation experiments as well as the data from the infection experiments 
(Fig. 19), it can be concluded that HepG2.2.15 cells cultivated on Cytodex-3 produce up 
to 18 fold more HBV virions and have simultaneously reduced secretion of subviral 
particles. 
 
Electron microscopy was used to show that HepG2.2.15 cells grew in a more three 
dimensional manner on microcarrier compared to the stationary cultivation method 
(Fig. 16). Cells grown this way that floated in suspension may have better nutrient 
diffusion and altered cell-cell interactions than those grown in stationary culture. 
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Estimation of cell number using Western blot analysis with an actin-specific antiserum 
showed that significantly fewer cells are found when cultivated on microcarriers 
(Fig. 18). However, this smaller amount of cells produced a significantly higher amount 
of viral particles than cells grown in flask culture. This correlates with recent reports 
[Friedrich, et al., 2005; Ozer, et al., 1996] describing a preference of HBV to replicate 
in quiescent cells. After 72h, however, there seems to be no significant difference in the 
proliferation rate as determined by the PCNA-specific Western blot (Fig. 20). From this 
it can be concluded that the different productivity observed under these two culture 
conditions is not due to the proliferation rate of the cells, and that alternative 
mechanisms are responsible. It has been shown that HBV replication depends on the 
integrity of the c-Raf-1/MEK/ERK-2 signaling cascade [Stockl, et al., 2003]. In cells 
grown on microcarrier, an increased activation of ERK-2 was observed, as 
demonstrated by increased phosphorylation (Fig. 20). Increased ERK-2 activation 
favors HBV replication, and may cause the increased replication observed here [Stockl, 
et al., 2003]. 
 
Together this data suggests that a combination of better nutrient diffusion and increased 
cell-cell interaction may cause the enhanced activation of the c-Raf/MEK/ERK-2 signal 
cascade, leading to increased HBV replication. It is reported that enhanced integrin 
interactions on the cell surface activates MAP kinase signaling [Hughes, et al., 1997], 
and culture conditions may alter these integrin interactions. It is evident that cell culture 
conditions have a tremendous impact on infection and replication studies. In 
HepG2.2.15 cells, cultivation on the microcarrier substrate Cytodex-3 offers an 
advantageous cost-value ratio with a maximal effect on virus production. 
 
6.2 PKC phosphorylation of HBV polymerase impairs virus 
replication 
 
Host cell signal transduction plays a crucial role in the HBV lifecycle e.g. by 
stimulation of MAP kinase signaling by viral transactivator proteins resulting in 
enhanced gene transcription as described above. But on the other hand HBV replication 
is decreased in proliferating hepatocytes [Friedrich, et al., 2005; Ozer, et al., 1996]. This 
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correlates with the induction of rapid liver regeneration observed during acute HBV 
infection. Protein kinase C (PKC) isoforms positively regulate liver compensatory 
growth [Tessitore, et al., 1995]. If PKC is inhibited in HBV replicating cells using 
Gö6876, HBV secretion increases in a dose dependent manner up to 1.8 fold (Fig. 30). 
This shows that activation of PKC impairs HBV replication. 
A highly conserved PKC recognition site was identified within the TP domain of human 
HBV genotypes using sequence alignment (Fig. 27). The HBV polymerase containing a 
pseudo-phosphorylated PKC recognition site (T53D) had impaired viral replication 
compared to the wild type polymerase, whereas when the PKC recognition site in TP 
was destroyed (T53I) no significant change in viral replication was observed (Fig. 31). 
Therefore PKC mediated phosphorylation of the HBV polymerase obviously impairs 
HBV replication. 
 
One can speculate on the benefit to HBV of a highly conserved recognition sequence 
that enables its negative regulation. It is conceivable that tight regulation of HBV 
replication during the S-phase increases host cell survival, and hence survival of the 
virus. 
 
6.3 Nuclear import of the HBV polymerase is mediated by a 
bipartite NLS and depends on CKII phosphorylation 
 
The HBV polymerase is a key enzyme in viral genome replication and remains 
covalently attached to the HBV genome after its reverse transcription. Although pgRNA 
recognition, genome replication, and virus assembly are well studied, the fate of the 
HBV polymerase in other phases of the viral lifecycle remains enigmatic. Particular 
questions addressing the mechanism of nuclear delivery of the HBV genome and the 
role of the bound polymerase are discussed controversially [Brandenburg, et al., 2005; 
Kann, et al., 1997; Rabe, et al., 2003]. One open question concerns the subcellular 
localization of the HBV polymerase. According to its molecular weight of about 
90 kDa, the HBV polymerase is too big to pass the nuclear pore complex by diffusion 
and be distributed equally between cytoplasm and nucleus. Yet, in duck HBV 
replication, non-encapsidated polymerase exists in addition to the encapsidated 
polymerase [Yao, et al., 2000]. The majority of the non-encapsidated duck HBV 
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polymerase is found in the cytoplasm, howerver a smaller fraction can be detected 
within the nucleus [Yao, et al., 2000]. Interestingly, in cells overexpressing HBV 
polymerase in the absence of other viral proteins, a fraction of HBV polymerase is 
found within the nucleus colocalized with the p11 protein of PML bodies [Choi, et al., 
2003]. Furthermore, Michael Kann and co-workers showed that purified HBV 
polymerase is sufficient to mediate nuclear import of the bound viral genome in the 
absence of viral core proteins [Kann, et al., 1997]. 
 
This evidence opens the questions of (i) the mechanism of nuclear import, and (ii) its 
relevance to the HBV lifecycle. Therefore, the second objective of this study was to 
identify motifs on the HBV polymerase which determine the subcellular localization of 
the P protein during viral lifecycle. 
 
By sequence alignment of HBV genotypes from different species we identified a 
potential protein kinase CKII recognition site in the TP domain of the HBV polymerase, 
which is flanked by the two basic clusters of a putative bipartite nuclear localization 
signal (NLS) (Fig. 27). More detailed analysis revealed that the predicted sequence 
indeed functions as a nuclear localization signal that when fused to GFP, leads to an 
enrichment of GFP in the nucleus compared to the even distribution of wild type GFP 
(Fig. 32). The NLS derived from the HBV polymerase has a weaker nuclear 
translocation capacity than the prototype bipartite NLS derived from nucleoplasmin 
[Dingwall, et al., 1982]. This correlates with the observation that only a minor fraction 
of HBV polymerase is localized within the nucleus (Fig. 26) [Choi, et al., 2003;  
Yao, et al., 2000]. Furthermore, a predominant nuclear localization would be fatal due 
to the fact that non-encapsidated polymerase has a key role during replication in the 
cytoplasm. It is very likely that additional factors regulate the HBV polymerase derived 
NLS functionality. 
 
The functionality of the HBV polymerase derived NLS depends on CKII-mediated 
phosphorylation within the two basic clusters of the NLS (Fig. 31-33). CKII is a loosely 
regulated kinase [Litchfield, 2003]. It can therefore be assumed that CKII exerts a 
housekeeping phosphorylation function [Meggio and Pinna, 2003]. In accordance with 
this, mimicking of constitutive phosphorylation as demonstrated with the T100D mutant 
does not result in increased virus replication compared to the wild type control 
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(Fig. 31). If the subcellular localization and function of the HBV polymerase is indeed 
subjected to tight control, it is unlikely that CKII exerts this function. 
 
CKII phosphorylation influences the subcellular localization of various nuclear proteins 
[Jans and Hubner, 1996]. For example CKII phosphorylation upstream of the NLS of 
simian virus 40 T-antigen enhances its nuclear import up to 40 fold [Jans and Jans, 
1994], but phosphorylation of one or two amino acid immediately upstream of the 
crucial amino acid of classic monopartite NLS seems to have inhibitory effects on 
karyopherin binding due to a disturbance of the NLS basicity [Harreman, et al., 2004]. 
In the case of bipartite nuclear localization signals this correlation is not evident. For 
example the spacer region of the functional bipartite NLS from the Agrobacterium 
tumefaciens nopaline protein contains four negatively charged aspartates, one located 
immediately at the downstream basic cluster [Howard, et al., 1992]. On the other hand 
an increase in hydrophobicity of the 10-12 amino acid spacer seems to decrease its 
functionality [Robbins, et al., 1991]. 
 
No obvious functional connection between the identified PKC phosphorylation site and 
the NLS was found. If both CKII and PKC recognition sites were either destroyed 
(T53D, T100I) or pseudo-phosphorylated (T53D, T100D) the expected rescue effect on 
viral replication was not observed. Instead the T100I as well the T53D substitutions 
affected the virus replication in a predominantly negative manner (Fig. 31). 
 
Phosphorylation can trigger changes in the tertiary structure of proteins. For example 
the reversible phosphorylation of the Na+/K+-ATPase triggers a conformational change 
that mediates the active transport of bound ions through a membrane [Reyes and 
Gadsby, 2006]. The tertiary structure of the HBV polymerase is not known, however 
ab initio modeling of the terminal protein domain predicts the possibility that CKII 
mediated phosphorylation could stabilize a tertiary structure with an exposed NLS 
(Fig. 34). This hypothesis has not been verified experimentally. 
 
The chaperone protein Hsp90 is an essential co-factor for pgRNA recognition by the 
HBV polymerase [Hu, et al., 2002]. The Hsp90 binding sites on the polymerase are 
localized within the TP domain and the RT domain [Cho, et al., 2000]. Interestingly, the 
identified NLS in the P protein is located within the Hsp90 binding site of the TP 
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domain. It is conceivable that the binding of Hsp90 to the HBV polymerase could mask 
the identified NLS, preventing nuclear translocation of the P protein prior to 
encapsidation. Furthermore, one can speculate that during nuclear import of the HBV 
genome, Hsp90 could reveal the NLS that trigger nuclear passage of the attached viral 
genome through the nuclear pore complex. This hypothesis is supported by the strong 
co-localization of Hsp90 and P protein that is observed in HBV polymerase expressing 
huh-7 cells (Fig. 26). Under these experimental conditions the majority of P protein is 
found in the cytoplasm colocalized with Hsp90, and only traces of P are found within 
the nucleus. The group of John Tavis found that the majority of non-encapsidated 
DHBV polymerase is bound to an unknown cytoplasmic structure [Yao, et al., 2000]. It 
is tempting to speculate that Hsp90, a binding partner of various cell structural proteins 
e.g. actin and tubulin, could mediate cytoplasmic retention of HBV polymerase. To 
prove this hypothesis, the straight forward experiment would be to measure the 
downregulation of Hsp90 in HBV polymerase expressing cells using an siRNA 
approach. This should increase the amounts of HBV polymerase in the nucleus. 
Unfortunately, this experiment was attempted but failed due to a dramatically enhanced 
Hsp90 expression in P protein expressing cells (Fig. 26). Also, the use of geldanamycin 
that inhibits the ATPase function of Hsp90 had no effects on the subcellular localization 
of the P protein in HBV polymerase expressing cells (data not shown). 
 
Transfection experiments were used to show that virus replication is almost completely 
abolished if the NLS or the CKII-site is destroyed by site directed mutagenesis 
(Fig. 31). This clearly demonstrates that this structural motif plays a crucial role in the 
viral lifecycle. Nuclear import of the viral genome is essential for the establishment of 
viral infection after initial binding and entry of the virus into the target cell. Moreover, 
re-entry of viral genomes into the nucleus during the viral replication process is 
essential for maintenance of the pool of transcriptional templates [Tuttleman, et al., 
1986]. An interesting aspect of this study is that inhibition of CKII activity, or 
destruction of the NLS or CKII site has a much stronger effect in infection or transient 
transfection experiments (Fig. 29 & 31) than in experiments performed with stably 
transfected cell lines (Fig. 29). In infection or transient transfection experiments only a 
very small pool of transcriptional templates exists to generate the 3.5 kb pgRNA. The 
re-entry of the viral genome is therefore essential to increase the intranuclear pool of 
transcriptional templates. In stable cell lines however, the pool of transcriptional 
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templates is increased by, but does not strictly depend on genome re-entry due to 
multiple integrations into the host genome. 
 
There are conflicting results about the pathways that enable the import of viral genomes 
into the nucleus. Based on digitonin permeabilized cells [Rabe, et al., 2003] or 
lipofection of nucleocapsids into hepatoma cells [Rabe, et al., 2006] it was described 
that complete nucleocapsids are able to migrate through the nuclear pore complex into 
the nucleus. Other studies using cell permeable nucleocapsids showed that the 
nucleocapsids do not enter the nucleus. The disassembly and release of the viral genome 
occurs in a perinuclear domain [Brandenburg, et al., 2005] raising the question of the 
import mechanism of the polymerase associated viral genome. Michael Kann and co-
workers reported in 1997 that the HBV polymerase is probably sufficient to mediate 
import of the bound viral genome into the nucleus of digitonin permeabilized huh-7 
cells, whereas the protein free genome itself stayed in the cytosol [Kann, et al., 1997]. 
 
The conclusion from these data leads to the model that the HBV nucleocapsid 
dissociates in a perinuclear domain and that the polymerase plays an essential role for 
the import of the viral genome and the subsequent amplification of cccDNA levels in 
the nucleus. It can not be excluded that HBV polymerase exerts additional functions to 
those established here. 
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APPENDIX 1 
 
Buffers and solutions 
 
ABP 
20 mM Tris hydrochloride 
25 mM beta-glycerol phosphate 
1 mM sodium ortho-vanadate 
20 mM 2-mercaptoethanol 
0.1 % (v/v) Tween-20 
pH 7.5 
 
AD 
100 mM Tris hydrochloride 
6 M urea 
pH 8.0 
 
Agarose gel sample buffer (6x) 
TAE (6x) 
30 % (v/v) glycerol 
0.1 mg/mL bromophenol blue 
 
AMS 
20 mM sodium acetate 
6 M urea 
2 % (v/v) ethanol 
pH 5.5 
 
AN 
TBS 
10 mM imidazole 
pH 8.0 
 
Anode buffer I 
0.3 M Tris base 
20 % (v/v) ethanol 
 
Anode buffer II 
25 mM Tris base 
20 % (v/v) ethanol 
 
ATP 
100 mM Tris hydrochloride 
6 M urea 
20 mM 2-mercaptoethanol 
pH 8.0 
 
Coomassie Brilliant Blue solution 
0.25 % (w/v) Coomassie 
Brilliant Blue G250 
10 % (v/v) acetic acid 
45 % (v/v) ethanol 
 
Coomassie Destain solution 
10 % (v/v) acetic acid 
30 % (v/v) ethanol 
 
CKII 
20 mM Tris hydrochloride 
50 mM potassium chloride 
10 mM imidazole 
20 mM 2-mercaptoethanol 
20 mM beta-glycerol phosphate 
0.1 mM sodium ortho-vanadate 
0.1 % (v/v) Tween-20 
pH 7.5 
 
EAB 
50 mM glycine 
150 mM sodium chloride 
pH 2.3 
 
EB 
10 mM Tris hydrochloride 
pH 8.5 
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ED 
100 mM Tris hydrochloride 
6 M urea 
pH 6.7 
 
EN 
TBS 
250 mM imidazole 
pH 8.0 
 
K (5x) 
125 mM Tris hydrochloride 
125 mM beta-glycerophosphate 
50 mM MgCl2 
5 mM DTT 
pH 7.5 
 
Kathode buffer 
40 mM 6-aminohexanoic acid 
 
LB medium 
10 g/L Bacto trypton 
5 g/L yeast extract 
5 g/L sodium chloride 
 
LG 
100mM Tris hydrochloride 
6 M guanidin hydrochlorid 
pH 8.0 
 
Mounting medium 
100 mM Tris-HCl 
10 % (w/v) Mowiol (polyvinyl alcohol)
25 % (w/v) glycerol 
2.5 % (w/v) DABCO 
 
NB 
0.2 M Mops 
50 mM sodium acetate 
10 mM EDTA 
pH 7.0 
 
NHS-A 
0.5 M ethanolamine 
0.5 M sodium chloride 
pH 8.3 
 
NHS-B 
0.1 M sodium acetate 
0.5 M sodium chloride 
pH 4.0 
 
NHS-D 
10 % (v/v) 10x PBS 
ad DMSO 
 
NHS-G 
2 M glycine 
pH 2.0 
 
PBS 
10 mM sodium phosphate dibasic 
3 mM potassium phosphate monobasic 
137 mM sodium chloride 
pH 7.4 
 
PBS-T 
PBS incl. 0.05 % (v/v) Tween-20 
 
R 
20 mM Tris hydrochloride 
134 mM sodium chloride 
10 % (v/v) glycerol 
10 % (w/v) sucrose 
20 mM 2-mercaptoethanole 
0.1 % (v/v) Tween-20 
pH 7.5 
 
RIPA 
20 mM Tris hydrochloride 
1 % (w/v) sodium desoxycholate 
1 % (v/v) Triton X-100 
0.1 % (w/v) sodium dedecyl sulfate 
150 mM sodium chloride 
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SB medium 
12 g/L Bacto trypton 
24 g/L yeast extract 
4 % (v/v) glycerol 
after autoclaving : 
170 mM potassium phosphate monob. 
720 nM potassium phosphate dibasic 
 
SDS-PAGE buffer 
25 mM Tris base 
0.2 M glycine 
0.1 % (w/v) sodium dodecyl sulfate 
 
SDS-PAGE sample buffer (6x) 
0.2 M Tris hydrochloride 
6 % (w/v) sodium dodecyl sulfate 
20 % (v/v) glycerol 
10 % dithiothreitol 
0.1 mg/mL bromophenol blue 
 
SE 
2.5 % (w/v) sodium carbonate 
5.4 mM formaldehyde 
 
SFi 
25 % (v/v) ethanol 
10 % (v/v) glacial acetic acid 
 
SKE 
0.1 % (w/v) silver nitrate 
3.4 mM formaldehyde 
 
SKO 
0.4 M sodium acetate 
30 % (v/v) ethanol 
4.4 mM sodium thiosulfate 
pentahydrate 
0.5 % (v/v) glutaraldehyde 
 
10x SSC 
150 mM trisodium citrate dehydrate 
1.5 M sodium chloride 
pH 7.0 
 
Stripping buffer 
62.5 mM Tris hydrochloride 
2 % (w/v) sodium dodecyl sulfate 
100 mM 2-mercaptoethanol 
pH 6.7 
 
TAE 
30 mM Tris hydrochloride 
20 mM acetic acid 
1 mM EDTA 
pH 8.0 
 
TBS 
20 mM Tris hydrochloride 
134 mM sodium chloride 
pH 7.4 
 
TE 
10 mM Tris hydrochloride 
1 mM EDTA 
pH 8.0 
 
WN 
TBS 
20 mM imidazole 
pH 8.0 
 
WD 
100 mM Tis hydrochloride 
6 M urea 
pH 6.7 
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APPENDIX 2 
 
Quantities of ammonium sulfate required to reach given degrees of saturation at +20 °C. 
Final percent saturation to be obtained
Starting 20 25 30 35 40 45 50 55 60 65 70 75 80 85 90 95 100
percent Amount of ammonium sulphate to add (grams) per liter of solution at +20 C
saturation
0 113 144 176 208 242 277 314 351 390 430 472 516 561 605 657 708 761
5 85 115 146 179 212 246 282 319 358 397 439 481 526 572 621 671 723
10 57 86 117 149 182 216 251 287 325 364 405 447 491 537 584 634 685
15 28 55 88 119 151 185 219 255 293 331 371 413 456 501 548 596 647
20 0 29 59 89 121 154 188 223 260 298 337 378 421 465 511 559 609
25 0 29 60 91 123 157 191 228 265 304 344 386 429 475 522 571
30 0 30 61 92 125 160 195 232 270 309 351 393 438 485 533
35 0 30 62 94 128 163 199 236 275 316 355 402 447 495
40 0 31 63 96 130 166 202 241 281 322 365 410 457
45 0 31 64 98 132 169 206 245 286 329 373 419
50 0 32 65 99 135 172 210 250 292 335 381
55 0 33 66 101 138 175 215 256 298 343
60 0 33 67 103 140 179 219 261 305
65 0 34 69 105 143 183 224 267
70 0 34 70 107 146 185 228
75 0 35 72 110 149 190
80 0 36 73 112 152
85 0 37 75 114
90 0 37 76
95 0 38
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